var title_f33_5_33872="Fusarium pneumonia x-ray";
var content_f33_5_33872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusarium pneumonia x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Alveolar infiltrates in a patient with Fusarium pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Garnica M, Nucci M. Emerging fungal infections. In: Pulmonary involvement in patients with hematological malignancies, 1st Ed, Azoulay E (Ed), Springer-Verlag, Berlin Heidelberg 2011, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33872=[""].join("\n");
var outline_f33_5_33872=null;
var title_f33_5_33873="Patient information: Managing pain during labor and delivery (The Basics)";
var content_f33_5_33873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/2/4131\">",
"         Patient information: How to tell when labor starts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Managing pain during labor and delivery (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/managing-pain-during-labor-and-delivery-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H301685716\">",
"      <span class=\"h1\">",
"       How painful is labor and delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The pain of labor and delivery is different for every woman. It depends on many factors, including the size of your baby and the way he or she is positioned in your uterus. The pain is usually mild early on in labor, but gets worse as you get closer to delivery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685723\">",
"      <span class=\"h1\">",
"       Should I make a plan to manage my pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Talk with your doctor, nurse, or midwife toward the end of pregnancy about how you can manage pain during labor and delivery. There are many ways to manage pain, and no 1 way works for everyone. The right decision is the one that is best for you.",
"     </p>",
"     <p>",
"      Although it&rsquo;s helpful to make a plan before you go into labor, keep in mind that your plan can change. That&rsquo;s because your labor can be more or less painful than you expect.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685730\">",
"      <span class=\"h1\">",
"       What are the different ways I can manage my pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, you can manage your pain with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Things you can do on your own",
"       </li>",
"       <li>",
"        Medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685737\">",
"      <span class=\"h1\">",
"       What can I do on my own to manage my pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help lessen your pain, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Change your body position",
"       </li>",
"       <li>",
"        Do relaxation or breathing exercises",
"       </li>",
"       <li>",
"        Take a shower or bath",
"       </li>",
"       <li>",
"        Have someone massage your lower back",
"       </li>",
"       <li>",
"        Put heat or cold on your lower back",
"       </li>",
"       <li>",
"        Listen to music",
"       </li>",
"       <li>",
"        Take a walk",
"       </li>",
"       <li>",
"        Have a &ldquo;doula&rdquo; help you &ndash; A doula is a person who stays with you during labor and delivery to support and reassure you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685744\">",
"      <span class=\"h1\">",
"       What if I want medicine to manage my pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want medicine during labor, let your doctor or nurse know. Doctors can use different medicines to help manage the pain of labor and delivery.",
"     </p>",
"     <p>",
"      These medicines work in different ways. Some medicines lessen pain, but still let you feel pressure and other sensations. Other medicines block pain as well as other sensations. The medicines are also given in different ways.",
"     </p>",
"     <p>",
"      Most women can have the following medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Opioid medicines &ndash; These are strong pain medicines that you can get through your IV or as a shot into your muscle. These medicines lessen pain, but do not make it go away completely.",
"       </li>",
"       <li>",
"        An epidural block &ndash; For an epidural block, a doctor will put a thin tube in your back. He or she will give you medicine through this tube. The medicine can remove all of the pain in the lower part of your body. An epidural block takes 10 to 20 minutes to start working.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685751\">",
"      <span class=\"h1\">",
"       What are the downsides of the different medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some downsides depend on the medicine itself, while others depend on how your body reacts to it.",
"     </p>",
"     <p>",
"      Some common downsides of an epidural block include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        After you get an epidural block, you will probably need to stay in bed and won&rsquo;t be able to walk around.",
"       </li>",
"       <li>",
"        You might have trouble pushing your baby out, because you won&rsquo;t have as much feeling in the lower part of your body.",
"       </li>",
"       <li>",
"        An epidural block can lower your blood pressure.",
"       </li>",
"       <li>",
"        After the birth, you might have a headache.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some common downsides of opioids include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Opioids can cause nausea or vomiting, or make you feel sleepy.",
"       </li>",
"       <li>",
"        These medicines can&rsquo;t be given too close to delivery because they can make the baby too sleepy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H301685800\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=see_link\">",
"       Patient information: How to tell when labor starts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33873?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16908 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33873=[""].join("\n");
var outline_f33_5_33873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685716\">",
"      How painful is labor and delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685723\">",
"      Should I make a plan to manage my pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685730\">",
"      What are the different ways I can manage my pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685737\">",
"      What can I do on my own to manage my pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685744\">",
"      What if I want medicine to manage my pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685751\">",
"      What are the downsides of the different medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301685800\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33874="Patient information: Finger dislocation (The Basics)";
var content_f33_5_33874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17185\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/15/20723\">",
"         Finger buddy taping",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/17/2323\">",
"         Patient information: Common finger injuries (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/5/3155\">",
"         Patient information: Finger fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25937\">",
"         Patient information: Cast and splint care (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Finger dislocation (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/finger-dislocation-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25362237\">",
"      <span class=\"h1\">",
"       What is a finger dislocation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A finger dislocation is when 1 of the bones in a finger joint is pushed or pulled out of position. The bone can be forced to the front, back, or side of the joint. When this happens, the finger bones don&rsquo;t line up correctly.",
"     </p>",
"     <p>",
"      A finger dislocation usually happens from a sudden injury. Sometimes, the injury causing the dislocation also causes a broken finger bone. The term doctors use for a broken finger bone is a &ldquo;finger fracture.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362252\">",
"      <span class=\"h1\">",
"       What are the symptoms of a finger dislocation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A finger dislocation causes pain and swelling around the joint. People can usually see or feel that their finger bone is out of position. Because the finger bone is out of position, people have trouble bending or straightening their finger.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362267\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you hurt your finger and you have symptoms of a finger dislocation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362282\">",
"      <span class=\"h1\">",
"       Is there a test for a finger dislocation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your symptoms, do an exam, and do an X-ray. An X-ray can show if your bone is out of position. It can also show if you have a finger fracture.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362297\">",
"      <span class=\"h1\">",
"       How is a finger dislocation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on how severe your finger dislocation is and if you also have a finger fracture.",
"     </p>",
"     <p>",
"      People with a severe dislocation or who also have a finger fracture are usually treated by a specialist called a hand surgeon. He or she will likely need to do surgery to put the bone back in the correct position.",
"     </p>",
"     <p>",
"      If your finger dislocation is not severe, the doctor can do a procedure to put your bone back in the correct position. Before he or she does this, you will get a shot to numb your finger or medicine to make you sleepy.",
"     </p>",
"     <p>",
"      During the procedure, the doctor will gently push or pull your finger back into the correct position. Then he or she will put a splint on your finger or tape your finger to the finger next to it, called &ldquo;buddy taping&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef82595 \" href=\"mobipreview.htm?20/15/20723\">",
"       picture 1",
"      </a>",
"      ). The doctor will do another X-ray to check that your bone is in the correct position. Most people need to wear a splint or use buddy taping for days to weeks, depending on which joint was dislocated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362312\">",
"      <span class=\"h1\">",
"       Is there anything else I should know about a finger dislocation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should know that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A dislocated joint has a higher chance of dislocating again.",
"       </li>",
"       <li>",
"        Finger joint stiffness or soreness can last for many months after a finger dislocation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25362327\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/5/3155?source=see_link\">",
"       Patient information: Finger fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/17/2323?source=see_link\">",
"       Patient information: Common finger injuries (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"       Patient information: Cast and splint care (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33874?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17185 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33874=[""].join("\n");
var outline_f33_5_33874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362237\">",
"      What is a finger dislocation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362252\">",
"      What are the symptoms of a finger dislocation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362267\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362282\">",
"      Is there a test for a finger dislocation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362297\">",
"      How is a finger dislocation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362312\">",
"      Is there anything else I should know about a finger dislocation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25362327\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/15/20723\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/17/2323?source=related_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33875="Nevus simplex (salmon patch) forehead";
var content_f33_5_33875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nevus simplex (salmon patch) of the forehead",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33875=[""].join("\n");
var outline_f33_5_33875=null;
var title_f33_5_33876="Weight loss treatments";
var content_f33_5_33876=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Weight loss treatments (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33876/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33876/contributors\" id=\"au6930\">",
"       George A Bray, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33876/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33876/contributors\" id=\"se859\">",
"       F Xavier Pi-Sunyer, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33876/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33876/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33876?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Obesity is a major international public health problem and Americans are among the heaviest people in the world. The percentage of obese people in the United States has risen steadily [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/1,2\">",
"      1,2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Many people find that although they initially lose weight by dieting, they quickly regain the weight after the diet ends. Because it so hard to keep weight off over time, it is important to have as much information and support as possible before starting a diet. You are most likely to be successful in losing weight and keeping it off when you believe that your body weight can be controlled.",
"    </p>",
"    <p>",
"     This article discusses how to get started with a weight loss plan, including changes in your behavior, what you eat, and weight loss medications. Weight loss surgery is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about weight loss is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"      \"Overview of therapy for obesity in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STARTING A WEIGHT LOSS PROGRAM",
"     </span>",
"    </p>",
"    <p>",
"     Some people like to talk to their health care professional to get help choosing the best plan, monitoring progress, and getting advice and support along the way.",
"    </p>",
"    <p>",
"     To know what treatment (or combination of treatments) will work best, determine your body mass index (BMI) and waist circumference (measurement). The BMI is calculated from your height and weight (",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"      calculator 1",
"     </a>",
"     and",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=see_link\">",
"      calculator 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A person with a BMI between 25 and 29.9 is considered overweight",
"      </li>",
"      <li>",
"       A person with a BMI of 30 or greater is considered to be obese",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A waist circumference greater than 35 inches (88 cm) in women and 40 inches (102 cm) in men increases the risk of obesity-related complications, such as heart disease and diabetes. People who are obese and who have a larger waist size may need more aggressive weight loss treatment than others. Talk to your health care professional for advice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Types of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Based on your measurements and your medical history, your doctor or nurse can determine what combination of weight loss treatments would work best for you. Treatments may include changes in lifestyle, exercise, dieting and, in some cases, weight loss medicines or weight loss surgery. Weight loss surgery, also called bariatric surgery, is reserved for people with severe obesity who have not responded to other weight loss treatments. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SETTING A WEIGHT LOSS GOAL",
"     </span>",
"    </p>",
"    <p>",
"     It is important to set a realistic weight loss goal. Your first goal should be to avoid gaining more weight and staying at your current weight (or within 5 percent or five pounds). Many people have a \"dream\" weight that is difficult or impossible to achieve.",
"    </p>",
"    <p>",
"     People at high risk of developing diabetes who are able to lose 5 percent of their body weight and maintain this weight will reduce their risk of developing diabetes by about 50 percent and reduce their blood pressure. This is a success.",
"    </p>",
"    <p>",
"     Losing more than 15 percent of your body weight and staying at this weight is an extremely good result, even if you never reach your \"dream\" or \"ideal\" weight.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      LIFESTYLE CHANGES",
"     </span>",
"    </p>",
"    <p>",
"     Programs that help you to change your lifestyle are usually run by psychologists, nutritionists, or other professionals. The goals of lifestyle changes are to help you change your eating habits, become more active, and be more aware of how much you eat and exercise, helping you to make healthier choices.",
"    </p>",
"    <p>",
"     This type of treatment can be broken down into three steps:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The triggers that make you want to eat",
"      </li>",
"      <li>",
"       Eating",
"      </li>",
"      <li>",
"       What happens after you eat",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Triggers to eat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Determining what triggers you to eat involves figuring out what foods you eat and where and when you eat. To figure out what triggers you to eat, keep a record for a few days of everything you eat, the places where you eat, how often you eat, and the emotions you were feeling when you ate.",
"    </p>",
"    <p>",
"     For some people, the trigger is related to a certain time of day or night. For others, the trigger is related to a certain place, like sitting at a desk working.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Eating",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can change your eating habits by breaking the chain of events between the trigger for eating and eating itself. There are many ways to do this. For instance, you can:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Limit where you eat to a few places (eg, dining room)",
"      </li>",
"      <li>",
"       Restrict the number of utensils (eg, only a fork) used for eating",
"      </li>",
"      <li>",
"       Drink a sip of water between each bite",
"      </li>",
"      <li>",
"       Chew your food a certain number of times",
"      </li>",
"      <li>",
"       Get up and stop eating every few minutes",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The types of foods we eat on a regular basis are related to whether we gain or lose weight over time. Whole grains, fruits, vegetables, nuts, and yogurt are associated with lower weight over four years, as contrasted with weight gain seen when eating french fried potatoes or chips, sugar-sweetened beverages, and red or processed meats [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      What happens after you eat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rewarding yourself for good eating behaviors can help you to develop better habits. This is not a reward for weight loss; instead, it is a reward for changing unhealthy behaviors toward healthy ones.",
"    </p>",
"    <p>",
"     Do not use food as a reward. Some people find money, clothing, or personal care (eg, a haircut, manicure, or massage) to be effective rewards. Treat yourself immediately after making better eating choices to reinforce the value of the good behavior.",
"    </p>",
"    <p>",
"     You need to have clear behavior goals and you must have a time frame for reaching your goals. Reward small changes along the way to your final goal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Other factors that contribute to successful weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changing your behavior involves more than just changing unhealthy eating habits; it also involves finding people around you to support your weight loss, reducing stress, and learning to be strong when tempted by food.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Establish a \"buddy\" system &mdash; Having a friend or family member available to provide support and reinforce good behavior is very helpful. The support person needs to understand your goals.",
"      </li>",
"      <li>",
"       Learn to be strong &mdash; Learning to be strong when tempted by food is an important part of losing weight. As an example, you will need to learn how to say \"no\" and continue to say no when urged to eat at parties and social gatherings. Develop strategies for events before you go, such as eating before you go or taking low-calorie snacks and drinks with you.",
"      </li>",
"      <li>",
"       Develop a support system &mdash; Having a support system is helpful when losing weight. This is why many commercial groups are successful. Family support is also essential; if your family does not support your efforts to lose weight, this can slow your progress or even keep you from losing weight.",
"      </li>",
"      <li>",
"       Positive thinking &mdash; People often have conversations with themselves in their head; these conversations can be positive or negative. If you eat a piece of cake that was not planned, you may respond by thinking, \"Oh, you stupid idiot, you've blown your diet!\" and as a result, you may eat more cake.",
"       <br/>",
"       <br/>",
"       A positive thought for the same event could be, \"Well, I ate cake when it was not on my plan. Now I should do something to get back on track.\" A positive approach is much more likely to be successful than a negative one.",
"      </li>",
"      <li>",
"       Reduce stress &mdash; Although stress is a part of everyday life, it can trigger uncontrolled eating in some people. It is important to find a way to get through these difficult times without eating or by eating low-calorie food, like raw vegetables. It may be helpful to imagine a relaxing place that allows you to temporarily escape from stress. With deep breaths and closed eyes, you can imagine this relaxing place for a few minutes.",
"      </li>",
"      <li>",
"       Self-help programs &mdash; Self-help programs like Weight Watchers&reg;, Overeaters Anonymous&reg;, and Take Off Pounds Sensibly (TOPS)&copy; work for some people. As with all weight loss programs, you are most likely to be successful with these plans if you make long-term changes in how you eat.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CHOOSING A DIET OR NEW EATING PLAN",
"     </span>",
"    </p>",
"    <p>",
"     A calorie is a unit of energy found in food. Your body needs calories to function. The goal of any diet is to burn up more calories than you eat. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"      \"Dietary therapy for obesity\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     How quickly you lose weight depends upon several factors, such as your age, gender, and starting weight.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Older people have a slower metabolism than young people, so they lose weight more slowly.",
"      </li>",
"      <li>",
"       Men lose more weight than women of similar height and weight when dieting because they use more energy.",
"      </li>",
"      <li>",
"       People who are extremely overweight lose weight more quickly than those who are only mildly overweight.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      How many calories do I need?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can estimate the number of calories you need per day based upon your current (or target) weight, gender, and activity level for women and for men [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     In general, it is best to choose foods that contain enough protein, carbohydrates, essential fatty acids, and vitamins. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      \"Patient information: Diet and health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Try not to drink alcohol or drinks with added sugar, and most sweets (candy, cakes, cookies), since they rarely contain important nutrients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Portion-controlled diets",
"     </span>",
"     &nbsp;&mdash;&nbsp;One simple way to diet is to buy packaged foods, like frozen low-calorie meals or meal-replacement canned drinks. A typical meal plan for one day may include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A meal-replacement drink or breakfast bar for breakfast",
"      </li>",
"      <li>",
"       A meal-replacement drink or a frozen low-calorie (250 to 350 calories) meal for lunch",
"      </li>",
"      <li>",
"       A frozen low-calorie meal or other prepackaged, calorie-controlled meal, along with extra vegetables for dinner",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This would give you 1000 to 1500 calories per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Low-fat diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;To reduce the amount of fat in your diet, you can:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Eat low-fat foods. Low-fat foods are those that contain less than 30 percent of calories from fat. Fat is listed on the food facts label (",
"       <a class=\"graphic graphic_figure graphicRef67956 \" href=\"mobipreview.htm?25/62/26597\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Count fat grams. For a 1500 calorie diet, this would mean about 45 g or fewer of fat per day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Low-carbohydrate diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low- and very-low-carbohydrate diets (eg, Atkins diet, South Beach diet) have become popular ways to lose weight quickly.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       With a very-low-carbohydrate diet, you eat between 0 and 60 grams of carbohydrates per day (a standard diet contains 200 to 300 grams of carbohydrates).",
"      </li>",
"      <li>",
"       With a low-carbohydrate diet, you eat between 60 and 130 grams of carbohydrates per day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Carbohydrates are found in fruits, vegetables, and grains (including breads, rice, pasta, and cereal), alcoholic beverages, and in dairy products. Meat and fish do not contain carbohydrates.",
"    </p>",
"    <p>",
"     Side effects of very-low-carbohydrate diets can include constipation, headache, bad breath, muscle cramps, diarrhea, and weakness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Mediterranean diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;The term \"Mediterranean diet\" refers to a way of eating that is common in olive-growing regions around the Mediterranean Sea. Although there is some variation in Mediterranean diets, there are some similarities. Most Mediterranean diets include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A high level of monounsaturated fats (from olive or canola oil, walnuts, pecans, almonds) and a low level of saturated fats (from butter).",
"      </li>",
"      <li>",
"       A high amount of vegetables, fruits, legumes, and grains (7 to 10 servings of fruits and vegetables per day).",
"      </li>",
"      <li>",
"       A moderate amount of milk and dairy products, mostly in the form of cheese. Use low-fat dairy products (skim milk, fat-free yogurt, low-fat cheese).",
"      </li>",
"      <li>",
"       A relatively low amount of red meat and meat products. Substitute fish or poultry for red meat.",
"      </li>",
"      <li>",
"       For those who drink alcohol, a modest amount (mainly as red wine) may help to protect against cardiovascular disease. A modest amount is up to one (4 ounce) glass per day for women and up to two glasses per day for men.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Which diet is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies have compared different diets, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Very-low-carbohydrate (Atkins&trade;)",
"      </li>",
"      <li>",
"       Macronutrient balance controlling glycemic load (Zone&reg;)",
"      </li>",
"      <li>",
"       Reduced-calorie (Weight Watchers&reg;)",
"      </li>",
"      <li>",
"       Very-low-fat (Ornish)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     No one diet is \"best\" for weight loss [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/5\">",
"      5",
"     </a>",
"     ]. Any diet will help you to lose weight if you stick with the diet. Therefore, it is important to choose a diet that includes foods you like.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Fad diets",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fad diets often promise quick weight loss (more than 1 to 2 pounds per week) and may claim that you do not need to exercise or give up favorite foods. Some fad diets cost a lot of money because you have to pay for seminars, pills, or packaged food. Fad diets generally lack any scientific evidence that they are safe and effective, but instead rely on \"before\" and \"after\" photos or testimonials.",
"    </p>",
"    <p>",
"     Diets that sound too good to be true usually are. These plans are a waste of time and money and are not recommended. A doctor, nurse, or nutritionist can help you find a safe and effective way to lose weight and keep it off.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WEIGHT LOSS MEDICINES",
"     </span>",
"    </p>",
"    <p>",
"     Taking a weight loss medicine may be helpful when used in combination with diet, exercise, and lifestyle changes. However, it is important to understand the risks and benefits of these medicines. It is also important to be realistic about your goal weight using a weight loss medicine; you may not reach your \"dream\" weight, but you may be able to reduce your risk of diabetes or heart disease. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"      \"Drug therapy of obesity\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Weight loss medicines may be recommended for people who have not been able to lose weight with diet and exercise who have a:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       BMI of 30 or more (",
"       <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       BMI between 27 and 29.9 and have other medical problems, such as diabetes, high cholesterol, or high blood pressure",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Only one weight loss medicine (orlistat) is approved in the United States for long-term use.",
"    </p>",
"    <p>",
"     Other weight loss medicines are available but are typically only approved for short-term use (up to 12 weeks).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Orlistat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Orlistat (Xenical&reg; 120 mg capsules) is a medicine that reduces the amount of fat your body absorbs from the foods you eat. A lower-dose version is now available without a prescription (Alli&reg; 60 mg capsules) in many countries, including the United States. The medicine is recommended three times per day, taken with a meal; you can skip a dose if you skip a meal or if the meal contains no fat.",
"    </p>",
"    <p>",
"     After one year of treatment with orlistat, the average weight loss is approximately 8 to 10 percent of initial body weight (4 percent more than in those who used lifestyle with a placebo). Cholesterol levels often improve and blood pressure sometimes falls. In people with diabetes, orlistat may help control blood sugar levels.",
"    </p>",
"    <p>",
"     Side effects occur in 15 to 10 percent of people and may include stomach cramps, gas, diarrhea, leakage of stool, or oily stools. These problems are more likely when you take orlistat with a high-fat meal (if more than 30 percent of calories in the meal are from fat). Side effects usually improve as you learn to avoid high-fat foods. Severe liver injury has been reported rarely in patients taking orlistat, but it is not known if orlistat caused the liver problems [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Dietary supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dietary supplements are widely used by people who are trying to lose weight, although the safety and efficacy of these supplements are often unproven. A few of the more common diet supplements are discussed below; none of these are recommended because they have not been studied carefully and there is no proof that they are safe or effective.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chitosan and wheat dextrin are ineffective for weight loss and their use is not recommended.",
"      </li>",
"      <li>",
"       Ephedra, a compound related to ephedrine, is no longer available in the United States due to safety concerns. Many nonprescription diet pills previously contained ephedra. Although some studies have shown that ephedra helps with weight loss, there can be serious side effects (psychiatric symptoms, palpitations, and stomach upset), including death.",
"      </li>",
"      <li>",
"       There are not enough data about the safety and efficacy of chromium, ginseng, glucomannan, green tea, hydroxycitric acid, L-carnitine, psyllium, pyruvate supplements, St. John&rsquo;s wort, and conjugated linoleic acid.",
"      </li>",
"      <li>",
"       Two supplements from Brazil, Emagrece Sim (also known as the Brazilian diet pill) and Herbathin dietary supplement, have been shown to contain prescription drugs.",
"      </li>",
"      <li>",
"       Hoodia gordonii is a dietary supplement derived from a plant in South Africa. It is not recommended because there is no proof that it is safe or effective.",
"      </li>",
"      <li>",
"       Bitter orange (Citrus aurantium) can increase your heart rate and blood pressure and is not recommended.",
"      </li>",
"      <li>",
"       Human chorionic gonadotropin is a hormonal preparation similar to luteinizing hormone that is given by injection. There have been several studies showing that these injections are not any better than placebo injections and it is thus not recommended [",
"       <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/7\">",
"        7",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WEIGHT LOSS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Weight loss surgery is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804423526\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569345\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=see_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38114?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=see_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/31/14835?source=see_link\">",
"      Patient information: Weight loss surgery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=see_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/51/38706?source=see_link\">",
"      Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/53/3923?source=see_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569454\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=see_link\">",
"      Approach to the patient with weight loss",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15816?source=see_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"      Dietary therapy for obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"      Drug therapy of obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=see_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"      Surgical management of severe obesity",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/weightcontrol.html\">",
"      www.nlm.nih.gov/medlineplus/weightcontrol.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://win.niddk.nih.gov/publications/choosing.htm\">",
"      file://win.niddk.nih.gov/publications/choosing.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/Resources/Cardio/upload/bilingual_obesity.pdf\">",
"      www.hormone.org/Resources/Cardio/upload/bilingual_obesity.pdf",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33876/abstract/8,9\">",
"      8,9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33876?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/1\">",
"      Yancy WS Jr, Olsen MK, Guyton JR, et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/2\">",
"      Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/3\">",
"      Mozaffarian D, Hao T, Rimm EB, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 364:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/4\">",
"      Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/5\">",
"      Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm (Accessed on January 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/7\">",
"      Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol 1995; 40:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/8\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement on Obesity. Gastroenterology 2002; 123:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33876/abstract/9\">",
"      Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142:525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_5_33876=[""].join("\n");
var outline_f33_5_33876=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STARTING A WEIGHT LOSS PROGRAM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SETTING A WEIGHT LOSS GOAL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           LIFESTYLE CHANGES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CHOOSING A DIET OR NEW EATING PLAN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WEIGHT LOSS MEDICINES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WEIGHT LOSS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/62/26597\" title=\"figure 1\">",
"           Nutrition label fat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33877="Heart failure";
var content_f33_5_33877=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Heart failure (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33877/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33877/contributors\" id=\"au5849\">",
"       Wilson S Colucci, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33877/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33877/contributors\" id=\"se241\">",
"       Stephen S Gottlieb, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/5/33877/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33877/contributors\" id=\"de1804\">",
"       Susan B Yeon, MD, JD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33877?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Heart failure (HF) is a condition that occurs when the heart cannot pump or fill with enough blood, which means that the heart must work harder to deliver blood to the body. The term \"heart failure\" is misleading because the heart does not completely fail or stop. Heart failure can be mild and cause minor symptoms, or it may be severe or even life-threatening. The most common symptoms of heart failure are shortness of breath, feeling tired, leg swelling, and other signs of fluid retention.",
"    </p>",
"    <p>",
"     Although heart failure is a serious condition, safe and effective treatments are available. Treatment can help you to feel better and live longer.",
"    </p>",
"    <p>",
"     This article discusses the most common causes, symptoms, and treatment of heart failure. More detailed information about heart failure is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"      \"Evaluation of the patient with suspected heart failure\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=see_link\">",
"      \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"      \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF HEART FAILURE",
"     </span>",
"    </p>",
"    <p>",
"     The heart is composed of four chambers: the two upper chambers are the right and left atria, and the two lower chambers are the right and left ventricles (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"mobipreview.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ). The left ventricle plays a key role because it pumps blood to the entire body. In a person with heart failure, the heart cannot adjust to the body's changing need for oxygen (for example, when climbing stairs).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HEART FAILURE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Heart failure is caused by a disease or condition that damages the heart. Fortunately, treating these conditions during the early stages can often prevent or slow development of heart failure. The most common causes of heart failure include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      High blood pressure (hypertension)",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with high blood pressure, the heart must work harder to pump blood. This increased workload can, over time, lead to an enlarged heart that does not work well. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Coronary heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Coronary heart disease causes narrowing of the blood vessels that supply (\"feed\") the heart muscle, reducing the flow of blood through the vessels. As a result, portions of the heart muscle are deprived of oxygen (especially during exercise, when the body needs more blood supply and oxygen), and the heart does not perform its work as well. Coronary heart disease can also lead to a heart attack (also called a myocardial infarction), which causes permanent damage to the heart muscle. Coronary heart disease can cause heart failure when it impairs from function of the heart.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Heart valve disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of conditions, including heart attack and aging, can damage the heart valves.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The valve can become narrowed (stenosed), which interferes with blood flow through the valve and increases pressure in the heart.",
"      </li>",
"      <li>",
"       In other cases, the valve can become leaky (insufficient), causing blood to flow backward (regurgitation). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=see_link\">",
"        \"Patient information: Mitral regurgitation (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some valves become both stenosed and regurgitant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Cardiomyopathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In cardiomyopathy, the heart muscle has been damaged, leading to an enlarged, poorly pumping heart. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"      \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      HEART FAILURE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     As the amount of blood pumped by the heart (the cardiac output) decreases, a variety of symptoms can develop.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Weakness, lightheadedness, or dizziness",
"      </li>",
"      <li>",
"       Shortness of breath, which might require you to be less active or sleep with several pillows",
"      </li>",
"      <li>",
"       A rapid heart rate, even while resting",
"      </li>",
"      <li>",
"       Swelling in the lower legs and feet (edema) or in the abdomen (ascites) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"        \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Feeling tired quickly",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HEART FAILURE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Heart failure is diagnosed based upon your medical history, an exam, and a series of tests. These tests can tell your doctor how well your heart is working and can help determine the cause of your heart failure. Tests may include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chest X-ray &mdash; A chest X-ray shows the size and shape of the heart and the large blood vessels in the chest. It also can show if there is fluid in the lungs.",
"      </li>",
"      <li>",
"       Electrocardiogram (EKG) &mdash; An EKG provides a picture of the electrical activity that causes the heart to beat. An EKG may detect conditions, such as an abnormal heart rhythm or a previous heart attack that could cause heart failure.",
"      </li>",
"      <li>",
"       Echocardiogram &mdash; An echocardiogram uses ultrasound (high-frequency sound waves) to assess the size and function of the heart's chambers and the structure and function of the heart valves. A follow-up echocardiogram can be done to see if your heart function changes over time.",
"      </li>",
"      <li>",
"       Exercise testing &mdash; An exercise test (\"stress test\") determines how well your heart performs during exercise. It is one way to look for signs of a shortage of blood supply to your heart caused by blockages in the coronary arteries. A doctor or nurse will see how your heart responds to exercise by looking at the EKG, blood pressure, and heart rate as you walk on a treadmill. In addition, pictures may be taken to measure the effect of exercise on the heart.",
"      </li>",
"      <li>",
"       Heart (cardiac) catheterization &mdash; Cardiac catheterization helps to measure how well the heart is functioning and provides pictures of the coronary arteries to look for blockages. During the test, a thin tube (the catheter) is inserted through a large blood vessel in the groin (or arm) and advanced into the heart. A dye is injected into the catheter to view the arteries and the structure of the heart by X-ray.",
"      </li>",
"      <li>",
"       Other tests &mdash; Cardiac catheterization is an invasive test that can have risks. Other tests, like CT or MRI, are sometimes used to look at the coronary arteries. This type of test is recommended only in specific situations.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HEART FAILURE COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Heart failure can cause symptoms and make you feel ill. In addition, it can cause dangerous, even life-threatening complications. The goal of treatments for heart failure is to reduce symptoms and reduce the chance of developing complications. The most common complications include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A weakened and enlarged heart muscle (called cardiomyopathy)",
"      </li>",
"      <li>",
"       Irregular heart rhythms (called arrhythmias), which can lead to blood clots or even a stroke",
"      </li>",
"      <li>",
"       Heart attack",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      HEART FAILURE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     In most people, heart failure is a chronic problem, meaning that it continues for months and years. Heart failure is generally treatable but rarely goes away completely. Treatment usually includes a combination of changes in your diet and lifestyle; medicines; and sometimes, a device to protect your heart from abnormal rhythms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Diet and lifestyle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changes in diet and lifestyle are often recommended to treat heart failure. The most common recommendations include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Decrease salt and water &mdash; Managing the amount of salt (sodium) in the foods you eat can help to keep heart failure under control. This usually means eating less than 2000 mg (2 grams) of sodium per day. Your doctor might give you more specific advice on sodium based on your condition. Low-sodium diets are discussed separately. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The amount of fluid you drink is also important. People with",
"     <strong>",
"      severe",
"     </strong>",
"     heart failure should drink less than 2 liters (66 ounces) of fluid per day. This includes all fluids. Your doctor might give you more specific guidance on fluid limits based on your condition.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Weigh yourself every day &mdash; To monitor your fluid levels, weigh yourself every day at the same time on the same scale (eg, in the morning after you urinate but before eating breakfast). Be sure to wear the same amount of clothing each time you weigh yourself. If your weight increases by 2 pounds (1 kilogram) in one day, call your doctor or nurse. Also, if your weight increases by 4 pounds (2 kg) in one week, call your doctor or nurse. Gaining weight suddenly is one sign that you may be retaining more fluid than you should be.",
"      </li>",
"      <li>",
"       Control your weight &mdash; If you are overweight, your heart must work harder to supply blood and oxygen to your body. Losing weight can help you to feel better and reduces the strain on your heart. On the other hand, losing a lot of weight quickly can be a sign of severe heart failure. For advice on weight management, talk to your doctor or nurse. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"        \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Stop smoking &mdash; Cigarette smoking increases your risk of having a heart attack and can worsen heart failure. If you smoke, talk to your doctor or nurse to get help with quitting. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Limit alcohol &mdash; Drinking too much alcohol is not good for your heart or your health generally. People with heart failure should not drink more than one serving of alcohol per day (for women) or two servings per day (for men). One serving is 12 ounces of beer or 5 ounces of wine. If your heart failure is related to drinking too much, you should stop drinking alcohol completely. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"        \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Cardiac rehab and exercise &mdash; Exercising most days of the week can help to reduce shortness of breath and fatigue, which are common problems in people with heart failure. Becoming more active can also help you to feel better. For exercise advice, talk to your doctor or nurse. They might recommend a cardiac rehab program to help you develop a safe exercise plan. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link&amp;anchor=H5#H5\">",
"        \"Patient information: Heart attack recovery (Beyond the Basics)\", section on 'Cardiac rehabilitation after heart attack'",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medicines are often used to treat heart failure symptoms; some medicines have even been proven to prolong life. It is very important to take these medicines on time every single day. If you cannot afford or have trouble taking your medicines, talk to your doctor or nurse.",
"    </p>",
"    <p>",
"     Some of the most commonly prescribed medicines include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Diuretic &mdash; People with heart failure often develop swelling (or edema) in the legs and fluid in the lungs. Medicines called diuretics (also called water pills) help the body get rid of the excess fluid. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"        \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       ACE inhibitor or ARB &mdash; ACE inhibitors and ARBs widen blood vessels and lower blood pressure, making it easier for your heart to pump. ACE inhibitors can sometimes cause a dry cough, in which case an ARB may be preferred. These medications can help prolong life.",
"      </li>",
"      <li>",
"       Beta blocker &mdash; Beta blockers are a type of medicine that can slow the heart rate and decrease blood pressure. This medication can help prolong life.",
"      </li>",
"      <li>",
"       Blood thinner &mdash; People with heart failure who have an irregular heart rhythm have an increased risk of developing a blood clot. This can be treated with a medicine to help prevent blood clots, sometimes called a \"blood thinner.\" The most commonly used medicines include warfarin (Coumadin&reg;) and aspirin. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"        \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Heart rhythm treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people with heart failure, a life-threatening abnormal heart rhythm (a type of ventricular arrhythmia) can develop. To return the heart to a normal rhythm, your doctor might recommend a device that shocks the heart and returns it to a normal rhythm. The device is called an implantable cardioverter-defibrillator (ICD). It is implanted under the skin in your upper chest. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Another potential problem in people with heart failure is abnormal electrical conduction in the heart. This can cause the walls of the left ventricle to contract out of sync, making the heart work less efficiently. A special type of pacemaker, called cardiac resynchronization therapy (CRT) or biventricular pacing, can treat this problem. A device that includes both CRT and ICD is available, if needed. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Surgery or stenting",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is sometimes recommended for people with heart failure who also have coronary heart disease or severe disease of the heart valves. This might include heart valve surgery or coronary artery bypass graft (CABG) surgery or both. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In some cases, coronary heart disease can be treated with a coronary artery angioplasty or stent procedure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Treatment for advanced heart failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart transplantation can be helpful for some people with severe heart failure that has not responded to other treatments. However, careful screening is required to ensure that heart transplantation is appropriate. In addition, the supply of hearts for transplant is limited, so most people must wait for months or even years before a heart is available. People who have a heart transplant are followed closely before and after surgery, since there are numerous risks. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=see_link\">",
"      \"Patient information: Heart transplantation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Your doctor might recommend a left ventricular assist device (LVAD) instead of transplantation OR while you wait for transplantation. These devices are implanted inside the chest and are designed to improve blood flow to the body when the heart pump is weakened. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=see_link\">",
"      \"Intermediate- and long-term mechanical cardiac support\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      HOW TO CARE FOR YOURSELF",
"     </span>",
"    </p>",
"    <p>",
"     Being diagnosed with heart failure can be frightening. There are a few basic guidelines that can help to manage your condition:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Always take your medicines. Do not skip doses when you feel better. If you cannot afford your medicines, talk to your doctor or nurse.",
"      </li>",
"      <li>",
"       Try to eat foods without added salt. More information about reducing salt is available. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Look for signs that your heart failure is getting worse (see below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;Call 911 for help if the following occur:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Severe shortness of breath",
"      </li>",
"      <li>",
"       Chest discomfort or pain that lasts more than 15 minutes and does not get better with rest or nitroglycerin",
"      </li>",
"      <li>",
"       Fainting or passing out",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Call your doctor or nurse if you develop any of the following, which can be signs of worsening heart failure:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Increasing or new shortness of breath",
"      </li>",
"      <li>",
"       New or worsened cough, especially if you are coughing up frothy or bloody material",
"      </li>",
"      <li>",
"       Worsened swelling in your legs or ankles",
"      </li>",
"      <li>",
"       Weight gain of 2 pounds (1 kilogram) in one day or 4 pounds (2 kg) in one week",
"      </li>",
"      <li>",
"       Fast or irregular heartbeat",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784965805\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112839535\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/13/21714?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/30/32226?source=see_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=see_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1939?source=see_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/34/37410?source=see_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/50/10018?source=see_link\">",
"      Patient information: Pleural effusion (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=see_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/14/15586?source=see_link\">",
"      Patient information: Myocarditis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/38/30307?source=see_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/25/2450?source=see_link\">",
"      Patient information: Tetralogy of Fallot (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/36/33346?source=see_link\">",
"      Patient information: Tricuspid regurgitation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=see_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/31/12787?source=see_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13956?source=see_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=see_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/6/35938?source=see_link\">",
"      Patient information: Stress-induced cardiomyopathy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112839550\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=see_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=see_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=see_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=see_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"      Prognosis of heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=see_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=see_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Failure Online",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.heartfailure.org/\">",
"      www.heartfailure.org",
"     </a>",
"     , also available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       European Society of Cardiology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.escardio.org/\">",
"      www.escardio.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/5/33877/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 4, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/5/33877?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33877/abstract/1\">",
"      Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33877/abstract/2\">",
"      Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical practice guideline No. 11 AHCPR publication No. 94-0612. Agency for Health Care Policy and Research, Rockville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33877/abstract/4\">",
"      Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33877/abstract/5\">",
"      Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997; 45:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33877/abstract/6\">",
"      Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26:1565.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_5_33877=[""].join("\n");
var outline_f33_5_33877=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF HEART FAILURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HEART FAILURE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           HEART FAILURE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HEART FAILURE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HEART FAILURE COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           HEART FAILURE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           HOW TO CARE FOR YOURSELF",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/14/11495\" title=\"figure 1\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33878="Genetics of the hemophilias";
var content_f33_5_33878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of the hemophilias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     W Keith Hoots, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Amy D Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33878/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/5/33878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemophilias are a group of related bleeding disorders that usually are inherited. Inherited bleeding disorders include abnormalities of coagulation factors as well as platelet function, the most common of which is von Willebrand disease. However, when the term \"hemophilia\" is used, it usually refers specifically to the following two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factor VIII deficiency (hemophilia A) &mdash; Hemophilia A affects 1 in 5000 to 10,000 males; roughly 60 percent have severe disease, with factor VIII activity less than 1 percent of normal.",
"     </li>",
"     <li>",
"      Factor IX deficiency (hemophilia B) &mdash; Hemophilia B affects 1 in 25,000 to 30,000 males; approximately one-half have mild to moderate disease, with factor IX activity greater than 1 percent of normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe factor VIII or factor IX deficiency leads to bleeding because of the role these factors play in the intrinsic pathway X-ase (ten-ase). The X-ase complex consists of activated factor IX (factor IXa) as the protease; activated factor VIII (factor VIIIa), calcium, and phospholipids as the cofactors; and factor X as the substrate (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"mobipreview.htm?31/51/32574\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22824?source=see_link\">",
"     \"Biology and normal function of factor VIII and factor IX\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the genetic basis of Hemophilia A and B. Diagnosis and management of patients with hemophilia are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hemophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link\">",
"       \"Treatment of hemophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"       \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of acquired inhibitors of factor VIII and other coagulation factors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia A and B are X-linked recessive disorders, which explains who is likely to bleed and the modes of genetic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/2\">",
"     2",
"    </a>",
"    ]. These hemophilias occur almost exclusively in a male having one defective copy of the relevant gene on his X chromosome (ie, he is hemizygous for the defect). Because the affected male will transmit a normal Y chromosome to all his sons and an abnormal X chromosome to all his daughters, his sons will not be affected and all of his daughters will be carriers (ie, they are heterozygous for the defect).",
"   </p>",
"   <p>",
"    Although female carriers have one normal allele, they may experience bleeding symptoms similar to those seen in a patient with \"mild\" deficiency. Therefore, their care and symptoms should be carefully evaluated. The female carrier will transmit the disorder to one-half of her sons, and one-half of her daughters will be carriers.",
"   </p>",
"   <p>",
"    However, some women have more symptomatic hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Possible explanations include inheritance of mutations from an affected male and a female carrier; half of the female offspring will be homozygous for the disease. Alternatively, loss of part or all of the normal X chromosome, as in Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/4\">",
"     4",
"    </a>",
"    ] or skewed inactivation of the normal X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/6\">",
"     6",
"    </a>",
"    ], may lead to symptomatic disease.",
"   </p>",
"   <p>",
"    Approximately one-third of patients with hemophilia do not have a family history of the disease and appear to represent novel mutational events, although somatic mosaicism in a parent or grandparent may explain some of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The large size of the factor VIII gene and the presence of \"hot spots\" within the gene are thought to predispose the gene to mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FACTOR VIII GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor VIII gene is one of the largest genes known, comprising about 0.1 percent of the X chromosome. The gene that encodes factor VIII is divided into 26 exons that span 186,000 base pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Factor VIII contains several areas of internal homology, consisting of a heavy chain with A1 and A2 domains; a connecting region with a B domain; and a light chain with A3, C1, and C2 domains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these domains have specific functions. For example, different epitopes on the C2 domain are responsible for binding to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells, von Willebrand factor (which importantly slows the catabolism of factor VIII), factor Xa, and thrombin. Two domains contribute to the binding of factor IXa (A2 domain and the",
"    <span class=\"nowrap\">",
"     A1/A3-C1-C2",
"    </span>",
"    dimer). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22824?source=see_link\">",
"     \"Biology and normal function of factor VIII and factor IX\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemophilia A genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of hemophilic genes has not demonstrated a uniform abnormality. Instead, numerous different mutations in the Factor VIII gene have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 200 affected genes, seven different mutations were demonstrated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/10\">",
"       10",
"      </a>",
"      ]. Four of them were transpositions of single bases, of which three transformed a codon for arginine into a stop codon, which arrested factor VIII synthesis and resulted in truncated factor VIII and severe hemophilia. The fourth mutation resulted in substitution of a single amino acid and mild hemophilias. The other three mutations involved deletion of several thousand nucleotides and produced severe hemophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1994 hemophilia A database indicated that more than 25 percent of unique nucleotide substitutions were caused by C-to-T transition at CpG dinucleotides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/15\">",
"       15",
"      </a>",
"      ]. The genetic defects of hemophilia A encompass deletions, insertions, and mutations throughout the gene. Approximately 5 percent have large (greater than 50 nucleotides) deletions in the gene.",
"     </li>",
"     <li>",
"      Approximately 40 percent of severe hemophilia A is caused by a major inversion of a section of the tip of the long arm of the X chromosome, one break point of which is situated within intron 22 of the gene. A consortium study, involving 22 laboratories from 14 countries, evaluated 2093 patients with severe hemophilia A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/16\">",
"       16",
"      </a>",
"      ]. Seven hundred forty patents (35 percent) had a type 1 (distal) factor VIII inversion, and 140 (7 percent) showed a type 2 (proximal) inversion. In 25 cases, the molecular analysis showed additional abnormal or polymorphic patterns. This observation has had a major impact upon carrier detection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hemophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 5 percent of patients who have hemophilia A also have normal levels of a dysfunctional factor VIII protein and are termed cross-reacting material (CRM)-positive. The majority of genetic alterations that result in CRM-positive hemophilia A are missense mutations within the A2-domain. The A2 subunit is essential for FVIIIa activity, and in one study, several of these mutants were found to have defective interaction with factor IXa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Searchable databases of hemophilia A mutations are available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/hemophilia/champs.html\">",
"     www.cdc.gov/ncbddd/hemophilia/champs.html",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.hadb.org.uk/\">",
"     www.hadb.org.uk",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Inhibitory antibodies develop in a proportion of patients with hemophilia A and B following replacement therapy. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Deficiency of factors VIII and V",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon cause of factor VIII deficiency is a mutation in the LMAN1 gene, which causes a rare autosomal recessive disease with combined deficiency of factor VIII and factor V. This gene encodes a protein that may act as a molecular chaperone of these and other secreted proteins from the endoplasmic reticulum to the Golgi apparatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The disease is associated with a moderate bleeding tendency, with plasma levels of 5 to 30 percent of normal for both factors.",
"   </p>",
"   <p>",
"    In other kindreds, the combined deficiency is associated with mutations in a gene on chromosome 2 called multiple coagulation factor deficiency 2 gene (MCFD2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/20\">",
"     20",
"    </a>",
"    ]. MCFD2 encodes a protein that forms a Ca(++)-dependent stoichiometric complex with LMAN1 and acts as a cofactor in the intracellular trafficking of factors V and VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=see_link&amp;anchor=H19#H19\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Combined deficiencies of factors V and VIII'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FACTOR IX GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene encoding factor IX is also located near the terminus of the long arm of the X chromosome. This 34 kb gene contains eight exons and seven introns; its protein product is one of the vitamin K dependent proteins. As such, it is the largest gene of this family and the only one present on the X chromosome. Further, the number of exons and splice junction types are highly conserved in homologous vitamin K dependent proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemophilia B genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia B is a markedly heterogeneous disorder with a wide range of plasma levels of factor IX and a variety of specific gene defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/21\">",
"     21",
"    </a>",
"    ]. The original factor IX deficient subject, Mr. Christmas, was a severely deficient patient whose mutation was cysteine206serine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most affected families show a unique mutation. For example, one study of 70 unrelated patients in the Rhone Alps in France with hemophilia B found two complete gene deletions in patients with antifactor IX inhibitor, six small",
"    <span class=\"nowrap\">",
"     insertions/deletions,",
"    </span>",
"    and 62 point mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/23\">",
"     23",
"    </a>",
"    ]. Two of these nucleotide substitutions were detected in 21 patients (30 percent), suggesting the existence of a local founder effect. Of the mutations, 13 were previously undescribed.",
"   </p>",
"   <p>",
"    A published hemophilia database lists, in an easily accessible form, all known factor IX mutations caused by small changes (base substitutions and short additions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deletions of &lt;30 bp) identified in hemophilia B patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/24\">",
"     24",
"    </a>",
"    ]. A searchable database is also available at",
"    <a class=\"external\" href=\"file://www.factorix.org/\">",
"     www.factorix.org",
"    </a>",
"    . Mutations have been detected in all regions of the Factor IX gene except the poly (A) site. Molecular events include 425 different amino substitutions and 143 short deletions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additions. Point mutations, the most common defect, can be associated with mild and severe hemophilia B. However, this database may not be completely representative of the disease for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The database over-represents defects leading to severe disease, as these are more likely to be analyzed and reported.",
"     </li>",
"     <li>",
"      Founder effects contribute to over-representations at some specific sites.",
"     </li>",
"     <li>",
"      Double mutations may be underrepresented because of lack of complete gene screening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deletions of the gene and some point mutations may be associated with absence of the factor IX antigen. However, absence of the FIX antigen is not always associated with inhibitor formation, with an incidence of approximately 3 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H27#H27\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Inhibitors in hemophilia B'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Leyden phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia B Leyden is a rare form of hemophilia B caused by a mutation in the factor IX gene promotor, rather than in the gene coding region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Several responsible point mutations have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/27\">",
"     27",
"    </a>",
"    ]. These promoter mutations disrupt the binding of transcription factors that increase factor IX expression after puberty. Thus, in individuals with the Leyden phenotype, factor IX levels increase following puberty, and these individuals often convert from a more severe to a milder clinical phenotype by adulthood.",
"   </p>",
"   <p>",
"    Leyden phenotype mutations cluster in a region of the factor IX promoter that spans from nucleotide -34 to +19, known as the Leyden Specific Region (LSR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/28\">",
"     28",
"    </a>",
"    ]. The normal LSR is regulated by transcription factors such as the liver enriched hepatocyte nuclear factor 4",
"    <span class=\"nowrap\">",
"     (HNF4/LF-A1)",
"    </span>",
"    and Ets1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/28\">",
"     28",
"    </a>",
"    ]. The pubertal hormone that causes these transcription factors to increase appears to be growth hormone, rather than androgens. In one instructive case, a 29-year-old man with mild Hemophilia B Leyden (baseline factor IX level of 1.2 International",
"    <span class=\"nowrap\">",
"     Units/mL)",
"    </span>",
"    developed an unintended and dramatic rise in factor IX levels (to 10.8 International",
"    <span class=\"nowrap\">",
"     Units/mL)",
"    </span>",
"    after using anabolic steroids for body building [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to patients with the Leyden phenotype, those with a point mutation at the -26 position of the factor IX promoter that disrupts an androgen-responsive element (Hemophilia B Brandenburg) do not show improved factor IX levels after puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dysfunctional protein mutants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to those families with hemophilia A, some families have antigen-positive (cross-reacting material positive, CRM+) defects, with clinical severity ranging from mild to severe. These patients have antigenic levels of factor IX that are near normal, but they have much lower factor IX activity levels. Approximately one-third of cases fall within this group. Mutations have been described that affect post-translational protein processing, gamma carboxylation and lipid binding, EGF domain function, zymogen activation, and substrate recognition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enzymatic activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defects in post-translational processing prevent cleavage of the 18-amino-acid propeptide of factor IX in factor IX Cambridge and factor IX Oxford [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In factor IX Chapel Hill, the first factor IX mutation characterized at the molecular level, activation of a zymogen is impaired because of the mutation of an arginine preceding a sessile bond [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many of these families display point mutations affecting various regions of the gene, ranging from the Gla region to defects in the 180 to 182 and 390 to 397 trypsin-like (catalytic) domain. In Factor IX Vancouver, for example, the codon for isoleucine 397 (ATA) is changed to a threonine codon (ACA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/34\">",
"       34",
"      </a>",
"      ]. Hydrogen bonding between the side chain hydroxyl group of threonine 397 and the carbonyl oxygen of tryptophan 385 reduces the ability of Factor IX Vancouver to bind factor X in a configuration favoring catalysis.",
"     </li>",
"     <li>",
"      Hemophilia Bm is a variant of hemophilia B that results in a dysfunctional protein, characterized by a prolonged prothrombin time when ox brain but not human brain is used as the source of thromboplastin. The Bm phenotype is associated with mutations at residue 180,181, or 182 near the amino terminus of the heavy chain and at residue 311, 364, 368, 390, 396, or 397 near the beta cleavage site of factor IX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33878/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Most have clinically severe disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/24/29058?source=see_link\">",
"       \"Patient information: Hemophilia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21506591\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked recessive disorders; thus, they occur almost exclusively in males who have one defective copy of the relevant gene on their X chromosome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemophilia A genes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hemophilia B genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the affected male will transmit a normal Y chromosome to all his sons and an abnormal X chromosome to all his daughters, his sons will not be affected and all of his daughters will be carriers (ie, heterozygotes). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although female carriers have one normal allele, they may experience bleeding symptoms similar to those seen in a patient with \"mild\" deficiency. The female carrier will transmit the disorder to one-half of her sons, and one-half of her daughters will be carriers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some women have more symptomatic hemophilia. Possible explanations include inheritance of mutations from an affected male and a female carrier, loss of part or all of the normal X chromosome, or skewed inactivation of the normal X chromosome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-third of patients with hemophilia do not have a family history of the disease and appear to represent novel mutational events. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis and management of hemophilia are discussed separately. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/1\">",
"      Brandstetter H, Bauer M, Huber R, et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92:9796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/2\">",
"      Hoyer LW. Hemophilia A. N Engl J Med 1994; 330:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/3\">",
"      MERSKEY C. The occurrence of haemophilia in the human female. Q J Med 1951; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/4\">",
"      Panarello C, Acquila M, Caprino D, et al. Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52. Cytogenet Cell Genet 1992; 59:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/5\">",
"      Pavlova A, Brondke H, M&uuml;sebeck J, et al. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 2009; 7:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/6\">",
"      Valleix S, Vinciguerra C, Lavergne JM, et al. Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A. Blood 2002; 100:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/7\">",
"      Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell 1985; 42:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/8\">",
"      Leuer M, Oldenburg J, Lavergne JM, et al. Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet 2001; 69:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/9\">",
"      Costa C, Frances AM, Letourneau S, et al. Mosaicism in men in hemophilia: is it exceptional? Impact on genetic counselling. J Thromb Haemost 2009; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/10\">",
"      Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/11\">",
"      Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/12\">",
"      Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/13\">",
"      Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/14\">",
"      Lawn RM, Vehar GA. The molecular genetics of hemophilia. Sci Am 1986; 254:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/15\">",
"      Tuddenham EG, Schwaab R, Seehafer J, et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22:4851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/16\">",
"      Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/17\">",
"      Amano K, Sarkar R, Pemberton S, et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/18\">",
"      Cunningham MA, Pipe SW, Zhang B, et al. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/19\">",
"      Neerman-Arbez M, Johnson KM, Morris MA, et al. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood 1999; 93:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/20\">",
"      Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003; 34:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/21\">",
"      Lillicrap D. The molecular basis of haemophilia B. Haemophilia 1998; 4:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/22\">",
"      Taylor SA, Duffin J, Cameron C, et al. Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis. Thromb Haemost 1992; 67:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/23\">",
"      Attali O, Vinciguerra C, Trzeciak MC, et al. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations. Thromb Haemost 1999; 82:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/24\">",
"      Giannelli F, Green PM, Sommer SS, et al. Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res 1998; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/25\">",
"      Veltkamp JJ, Meilof J, Remmelts HG, et al. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol 1970; 7:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/26\">",
"      Bri&euml;t E, Bertina RM, van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/27\">",
"      Picketts DJ, Mueller CR, Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994; 84:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/28\">",
"      Kurachi S, Huo JS, Ameri A, et al. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci U S A 2009; 106:7921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/29\">",
"      Rimmer EK, Seftel MD, Israels SJ, Houston DS. Unintended benefit of anabolic steroid use in hemophilia B leiden. Am J Hematol 2012; 87:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/30\">",
"      Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/31\">",
"      Diuguid DL, Rabiet MJ, Furie BC, et al. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci U S A 1986; 83:5803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/32\">",
"      Bentley AK, Rees DJ, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell 1986; 45:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/33\">",
"      Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A 1983; 80:4200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/34\">",
"      Geddes VA, Le Bonniec BF, Louie GV, et al. A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver. J Biol Chem 1989; 264:4689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/35\">",
"      Taylor SA, Liddell MB, Peake IR, et al. A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm. Br J Haematol 1990; 75:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33878/abstract/36\">",
"      Hamaguchi N, Roberts H, Stafford DW. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm. Biochemistry 1993; 32:6324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1311 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33878=[""].join("\n");
var outline_f33_5_33878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21506591\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FACTOR VIII GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemophilia A genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Deficiency of factors VIII and V",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FACTOR IX GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemophilia B genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Leyden phenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dysfunctional protein mutants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21506591\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1311|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/51/32574\" title=\"figure 1\">",
"      Coagulation cascade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22824?source=related_link\">",
"      Biology and normal function of factor VIII and factor IX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/24/29058?source=related_link\">",
"      Patient information: Hemophilia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33879="Clofarabine: Drug information";
var content_f33_5_33879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clofarabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/44/44740?source=see_link\">",
"    see \"Clofarabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29941?source=see_link\">",
"    see \"Clofarabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16057714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider prophylactic corticosteroids (hydrocortisone 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS), hydration and antihyperuricemic therapy (to reduce the risk of tumor lysis syndrome/hyperuricemia), and prophylactic antiemetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     Adults &le;21 years: I.V.: 52 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1 through 5; repeat every 2-6 weeks; subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle (subsequent cycles may be administered when ANC &ge;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia, relapsed/refractory (ALL; unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Monotherapy:",
"     </i>",
"     Induction: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; may repeat induction cycle once in 3-6 weeks (depending on marrow response and recovery) (Kantarjian, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Combination therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (in combination with cytarabine); may repeat one time after day 28 (if needed) (Advani, 2010)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (in combination with conventional chemotherapy) (Pigneux, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days (in combination with cytarabine) for one cycle (Advani, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute myelocytic leukemia (AML) (unlabeled use):",
"     </b>",
"     Adults &ge;60 years: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Monotherapy (Kantarjian, 2010):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; may repeat one time after day 28 (if needed) with 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days for up to a maximum total 6 cycles, including induction cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Combination therapy with cytarabine (Faderl, 2008):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; may repeat one time if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 4-7 weeks for up to a total of 12 consolidation cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing in obesity:",
"     </b>",
"     <i>",
"      ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:",
"     </i>",
"     Utilize full weight-based chemotherapy dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F153007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29941?source=see_link\">",
"      see \"Clofarabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider prophylactic corticosteroids (hydrocortisone 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS), hydration and antihyperuricemic therapy (to reduce the risk of tumor lysis syndrome/hyperuricemia), and prophylactic antiemetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     Children &ge;1 year: I.V.: 52 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1 through 5; repeat every 2-6 weeks; subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle (subsequent cycles may be administered when ANC &ge;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F152999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Clofarabine undergoes renal elimination and exposure is increased as creatinine clearance decreases (Bonate, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      NCCN AML guidelines (v.2.2012):",
"     </i>",
"     Adults &gt;60 years with creatinine clearance &lt;60 mL/minute: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F153000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution (has not been studied). Canadian labeling contraindicates use in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6872379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     lasting &ge;4 weeks: Reduce dose by 25% for next cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clinically significant infection:",
"     </i>",
"     Withhold treatment until infection is under control, then restart at full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Grade 3 toxicity excluding infection, nausea and vomiting, and transient elevations in transaminases and bilirubin:",
"     </i>",
"     Withhold treatment; may reinitiate with a 25% dose-reduction with resolution or return to baseline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Grade &ge;3 increase in creatinine or bilirubin:",
"     </i>",
"     Discontinue; may reinitiate with 25% dosage reduction when creatinine or bilirubin return to baseline and patient is stable; administer antihyperuricemic therapy for elevated uric acid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Grade 4 toxicity (noninfectious):",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Capillary leak or systemic inflammatory response syndrome (SIRS) early signs/symptoms (eg, hypotension, tachycardia, tachypnea, pulmonary edema):",
"     </i>",
"     Discontinue clofarabine; institute supportive measures. May consider reinitiating with a 25% dose reduction after patient is stable and organ function recovers to baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hypotension due to any cause (Canadian labeling):",
"     </i>",
"     Discontinue clofarabine; if hypotension resolves without pharmacologic intervention, may reinitiate with 25% dosage reduction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clolar&reg;: 1 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion: Over 1-2 hours (Faderl, 2008; Kantarjian, 2003; Kantarjian, 2010). Continuous I.V. fluids are encouraged to decrease adverse events and tumor lysis effects. Hypotension may be a sign of capillary leak syndrome or systemic inflammatory response syndrome (SIRS). Discontinue if the patient becomes hypotensive during administration; may consider therapy reinitiation with a 25% dose reduction after return to baseline. Do not administer any other medications through the same intravenous line.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3051225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Do not administer other medications through the same intravenous line.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute lymphoblastic leukemia (ALL) in children (ages 1-21 years)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F153011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed/refractory acute lymphoblastic leukemia (ALL) in adults; treatment of acute myeloid leukemia (AML) in adults &ge;60 years of age",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clofarabine may be confused with cladribine, clevidipine, cytarabine, nelarabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (35%), hypotension (29%; grade 3: 11%; grade 4: 8%), flushing (19%), hypertension (13%), edema (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (43%), fever (39%), chills (34%), fatigue (34%), anxiety (21%), pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (43%), rash (38%), petechiae (26%), palmar-plantar erythrodysesthesia syndrome (16%), erythema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (78%; grades 3/4: 9%), nausea (73%; grades 3/4: 15%), diarrhea (56%), abdominal pain (8% to 35%), anorexia (30%), gingival bleeding (17%), mucosal inflammation (16%), oral candidiasis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (grades 3/4: 88%), anemia (83%; grades 3/4: 75%), lymphopenia (grades 3/4: 82%),  thrombocytopenia (81%; grades 3/4: 80%), neutropenia (grades 3/4: 10% to 64%), febrile neutropenia (55%; grade 4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (81%; grades 3/4: 43% to 44%), AST increased (74%; grades 3/4: 36%), bilirubin increased (45%; grades 3/4: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Limb pain (30%), myalgia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (50%; grades 3/4: 8%), hematuria (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (27%), dyspnea (13%), pleural effusion (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (83%; includes bacterial, fungal, and viral), sepsis/septic shock (17%), catheter-related infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Pericardial effusion (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Irritability (10%), lethargy (10%), somnolence (10%), agitation (5%), mental status change (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cellulitis (8%), pruritic rash (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Proctalgia (8%), clostridium colitis (7%), stomatitis (7%), oral mucosal petechiae (5%), cecitis (1% to 4%), pancreatitis (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (10%), bone pain (10%), weakness (10%), arthralgia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (10%), respiratory distress (10%), tachypnea (9%), upper respiratory tract infection (5%), pulmonary edema (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes simplex (10%), bacteremia (9%), candidiasis (7%), herpes zoster (7%), staphylococcus bacteremia (6%), tumor lysis syndrome (grade 3: 6%), capillary leak syndrome (4%), hypersensitivity (1% to 4%), SIRS (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Bone marrow failure, dermatitis, gastrointestinal hemorrhage,  hallucination, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease),   hepatomegaly, hypokalemia, hypophosphatemia, left ventricular systolic function decreased, right ventricular pressure increased, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the U.S. product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to clofarabine or any component of the formulation; symptomatic CNS involvement; history of serious heart, liver, kidney, or pancreas disease; severe hepatic impairment (AST and/or ALT &gt;5 x ULN, and/or bilirubin &gt;3 x ULN); severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt; 30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-dependent, reversible myelosuppression (neutropenia, thrombocytopenia, and anemia) is common; may be severe and prolonged. Monitor blood counts and platelets daily during treatment, then 1-2 times weekly or as necessary. May be at increased risk for infection due to neutropenia. Monitor for signs and symptoms of infection and treat promptly if infection develops; may require discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Capillary leak syndrome/systemic inflammatory response syndrome (SIRS): Cytokine release syndrome (eg, tachypnea, tachycardia, hypotension, pulmonary edema) may develop into capillary leak syndrome/SIRS, and organ dysfunction; discontinue with signs/symptoms of SIRS or capillary leak syndrome (rapid-onset respiratory distress, hypotension, pleural/pericardial effusion, and multiorgan failure) and consider supportive treatment with diuretics, corticosteroids, and/or albumin. Prophylactic corticosteroids may prevent or diminish the signs/symptoms of cytokine release.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Monitor blood pressure during 5 days of treatment; discontinue if hypotension develops. Monitor if on concurrent medications known to affect blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Transaminases and bilirubin may be increased during treatment; transaminase elevations generally occur within 10 days of administration and persist for &le;15 days. In some cases, hepatotoxicity was severe and fatal. The risk for hepatotoxicity, including hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), is increased in patients who have previously undergone a hematopoietic stem cell transplant; discontinue if SOS is suspected. Avoid the concomitant use of drugs that may cause hepatotoxicity. Monitor liver function closely; may require therapy interruption or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: The risk for infections, including opportunistic infection or sepsis, is increased due to prolonged neutropenia and immunocompromised state. Monitor for signs and symptoms of infection and treat promptly if infection develops; may require therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Elevated creatinine, acute renal failure, and hematuria were observed in clinical studies. Monitor renal function closely; may require dosage reduction or therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome/hyperuricemia: Tumor lysis syndrome may occur as a consequence of leukemia treatment, including treatment with clofarabine, usually occurring in the first treatment cycle. May lead to life-threatening acute renal failure; adequate hydration and prophylactic antihyperuricemic therapy throughout treatment will reduce the risk/effects of tumor lysis syndrome; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Has not been studied in patients with hepatic impairment; use with caution. Canadian labeling contraindicates use in severe impairment or with history of serious hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: A pharmacokinetic study demonstrated that systemic exposure increases as creatinine clearance decreases (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) (Bonate, 2011). Dosage reduction required for moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute); use with caution in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (has not been studied). Minimize the use of drugs known to cause renal toxicity during the 5-day treatment period. Canadian labeling contraindicates use in severe impairment or with history of serious kidney disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and resorptions were observed in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6871935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be avoided during clofarabine treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clolar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (20 mL): $3007.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (daily during treatment, then 1-2 times weekly or as necessary); liver and kidney function (during 5 days of clofarabine administration); blood pressure, cardiac function, and respiratory status during infusion; signs and symptoms of tumor lysis syndrome, infection, and cytokine release syndrome (tachypnea, tachycardia, hypotension, pulmonary edema); hydration status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Clofazic (AR);",
"     </li>",
"     <li>",
"      Evoltra (AT, AU, BE, CZ, DK, EE, FR, GB, GR, IE, IT, MY, NL, NO, NZ, PL, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate. Clofarabine 5'-triphosphate decreases cell replication and repair as well as causing cell death. To decrease cell replication and repair, clofarabine 5'-triphosphate competes with deoxyadenosine triphosphate for the enzymes ribonucleotide reductase and DNA polymerase. Cell replication is decreased when clofarabine 5'-triphosphate inhibits ribonucleotide reductase from reacting with deoxyadenosine triphosphate to produce deoxynucleotide triphosphate which is needed for DNA synthesis. Cell replication is also decreased when clofarabine 5'-triphosphate competes with DNA polymerase for incorporation into the DNA chain; when done during the repair process, cell repair is affected. To cause cell death, clofarabine 5'-triphosphate alters the mitochondrial membrane by releasing proteins, an inducing factor and cytochrome C.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 172 L/m",
"     <sup>",
"      2",
"     </sup>",
"     or 5.8 L/kg (Bonate, 2011); Elderly: 268 L/kg (Bonate, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 47%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Intracellulary by deoxycytidine kinase and mono- and diphosphokinases to active metabolite clofarabine 5&prime;-triphosphate; limited hepatic metabolism (0.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: ~5 hours; Children and Adults: 7 hours (Bonate, 2011); half-life may be increased in elderly and in patients with renal impairment (Bonate, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (49% to 60%, as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Advani AS, Gundacker HM, Sala-Torra O, et al, &ldquo;Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine and Cytarabine for Relapsed or Refractory Acute Lymphocytic Leukaemia,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2010, 151(5):430-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/21113977/pubmed\" id=\"21113977\" target=\"_blank\">",
"        21113977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonate PL, Cunningham CC, Gaynon P, et al, &ldquo;Population Pharmacokinetics of Clofarabine and its Metabolite 6-Ketoclofarabine in Adult and Pediatric Patients With Cancer,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2011, 67(4):875-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/20582417/pubmed\" id=\"20582417\" target=\"_blank\">",
"        20582417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faderl S, Ravandi F, Huang X, et al, &ldquo;A Randomized Study of Clofarabine versus Clofarabine Plus Low-Dose Cytarabine as Front-Line Therapy for Patients Aged 60 Years and Older With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(5):1638-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/18565853/pubmed\" id=\"18565853\" target=\"_blank\">",
"        18565853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Gandhi V, Chan KW, et al, &ldquo;Clofarabine, a Novel Nucleoside Analog, is Active in Pediatric Patients With Advanced Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(3):784-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/14551141/pubmed\" id=\"14551141\" target=\"_blank\">",
"        14551141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Gaynon PS, Razzouk BI, et al, &ldquo;Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(12):1917-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/16622268/pubmed\" id=\"16622268\" target=\"_blank\">",
"        16622268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Gandhi V, Cortes J, et al, &ldquo;Phase 2 Clinical and Pharmacologic Study of Clofarabine in Patients With Refractory or Relapsed Acute Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(7):2379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/12791647/pubmed\" id=\"12791647\" target=\"_blank\">",
"        12791647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, Erba HP, Claxton D, et al, &ldquo;Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(4):549-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/5/33879/abstract-text/20026805/pubmed\" id=\"20026805\" target=\"_blank\">",
"        20026805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Acute Myeloid Leukemia,&rdquo; Version 2, 2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pigneux A, Sauvezie M, Vey N, et al, &ldquo;Clofarabine Combinations in Adults With Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):2586 [abstract 2586 from the 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9220 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33879=[""].join("\n");
var outline_f33_5_33879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153014\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152998\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153007\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152999\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153000\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6872379\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152978\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152966\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152980\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3051225\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152979\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153011\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401601\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153012\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152983\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152968\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299065\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152972\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152986\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153003\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6871935\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323073\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152976\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038584\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152967\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152982\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/44/44740?source=related_link\">",
"      Clofarabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29941?source=related_link\">",
"      Clofarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33880="Lumbar triangle of Petit";
var content_f33_5_33880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81616%7ESURG%2F58976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81616%7ESURG%2F58976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Lumbar triangle of Petit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 619px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Petit triangle nerves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33880=[""].join("\n");
var outline_f33_5_33880=null;
var title_f33_5_33881="Taenia proglottids";
var content_f33_5_33881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taenia proglottids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Mature proglottids of",
"    <em>",
"     T. saginata",
"    </em>",
"    . Injection of India ink into the genital pore in figure B helps with the visualization of the primary lateral uterine branches. Note the number of branches (&gt;12).",
"    <br/>",
"    (C) Cross-section of a proglottid of",
"    <em>",
"     Taenia",
"    </em>",
"    spp, stained with hematoxylin and eosin (H&amp;E). Note the thick outer tegument and the loose parenchyma filling the body. Calcareous corpuscles (red arrows), characteristic of the cestodes, can be seen in the parenchyma. Eggs (blue arrows) can also be seen.",
"    <br/>",
"    (D) Higher magnification of figure C showing a close-up of the eggs. Note the characteristic striations, typical for the taeniids. Not visible in these images are the hooks commonly seen in cestode eggs. Hooks do not stain with H&amp;E but are refractile and visible with fine focusing of the microscope.",
"    <br/>",
"    (E) Close-up of a cross-section of a",
"    <em>",
"     Taenia",
"    </em>",
"    spp proglottid stained with hematoxylin and eosin (H&amp;E), showing numerous calcareous corpuscles (yellow arrows).",
"    <br/>",
"    (F) Close-up of a cross-section of a",
"    <em>",
"     Taenia",
"    </em>",
"    spp proglottid stained with hematoxylin and eosin (H&amp;E), showing numerous calcareous corpuscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Taeniasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Taeniasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Taeniasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33881=[""].join("\n");
var outline_f33_5_33881=null;
var title_f33_5_33882="Causes and evaluation of hyperkalemia in adults";
var content_f33_5_33882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and evaluation of hyperkalemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/5/33882/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/5/33882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is a common clinical problem. Potassium enters the body via oral intake or intravenous infusion, is largely stored in the cells, and is then excreted in the urine. The major causes of hyperkalemia are increased potassium release from the cells and, most often, reduced urinary potassium excretion (",
"    <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the causes and evaluation of hyperkalemia. The clinical manifestations, treatment, and prevention of hyperkalemia, as well as a detailed discussion of hypoaldosteronism (an important cause of hyperkalemia), are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7397120\">",
"    <span class=\"h1\">",
"     BRIEF REVIEW OF POTASSIUM PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of potassium physiology is helpful when approaching patients with hyperkalemia. Total body potassium stores are approximately 3000 meq (50 to 55",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    body weight). In contrast to sodium, which is the major cation in the extracellular fluid and has a much lower concentration in the cells, potassium is primarily an intracellular cation, with the cells containing approximately 98 percent of body potassium. The intracellular potassium concentration is approximately 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    compared with 4 to 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the extracellular fluid. The difference in distribution of the two cations is maintained by the Na-K-ATPase pump in the cell membrane, which pumps sodium out of and potassium into the cell in a 3:2 ratio.",
"   </p>",
"   <p>",
"    The ratio of the potassium concentrations in the cells and the extracellular fluid is the major determinant of the resting membrane potential across the cell membrane, which sets the stage for the generation of the action potential that is essential for normal neural and muscle function. Thus, both hyperkalemia and hypokalemia can cause muscle paralysis and potentially fatal cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link&amp;anchor=H3819731#H3819731\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Manifestations of hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of hyperkalemia can be best understood after a brief review of normal potassium homeostasis. The plasma potassium concentration is determined by the relationship among potassium intake, the distribution of potassium between the cells and the extracellular fluid, and urinary potassium excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133155018\">",
"    <span class=\"h2\">",
"     Regulation of urinary potassium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, dietary potassium is absorbed in the intestines and then largely excreted in the urine, a process that is primarily determined by potassium secretion by the principal cells in the two segments that follow the distal tubule: the connecting segment and cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There are three major factors that stimulate principal cell potassium secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in plasma potassium concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      potassium intake",
"     </li>",
"     <li>",
"      An increase in aldosterone secretion",
"     </li>",
"     <li>",
"      Enhanced delivery of sodium and water to the distal potassium secretory site",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ingestion of a potassium load leads initially to the uptake of most of the excess potassium by cells in muscle and the liver, a process that is facilitated by insulin and the beta-2-adrenergic receptors, both of which increase the activity of Na-K-ATPase pumps in the cell membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Some of the ingested potassium remains in the extracellular fluid, producing a mild elevation in the plasma potassium concentration.",
"   </p>",
"   <p>",
"    The increase in plasma potassium stimulates the secretion of aldosterone, which enhances both sodium reabsorption and potassium secretion in the principal cells (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ). The increase in sodium reabsorption is mediated primarily by an increase in the number of open sodium channels in the luminal membrane of the principal cells. The reabsorption of cationic sodium makes the lumen more electronegative, thereby enhancing the electrical gradient that promotes the secretion of potassium from the cells into the tubular fluid via potassium channels in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ). Aldosterone also increases the number and activity of basolateral Na-K-ATPase pumps in principal cells, which facilitates both sodium reabsorption and potassium secretion. The net effect is that most of the potassium load is excreted within six to eight hours.",
"   </p>",
"   <p>",
"    Both cellular uptake and urinary excretion of an acute potassium load are impaired in patients with advanced acute or chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H270425989\">",
"     'Acute and chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Potassium adaptation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is a rare occurrence in normal individuals because the cellular and urinary responses prevent significant potassium accumulation in the extracellular fluid. Furthermore, the efficiency of potassium excretion is enhanced if potassium intake is increased, thereby allowing what might otherwise be a fatal potassium load to be tolerated. This phenomenon, called",
"    <strong>",
"     potassium adaptation",
"    </strong>",
"    , is mostly due to the ability to more rapidly excrete potassium in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in rats have shown that potassium adaptation begins after a single potassium-containing meal. In one study, for example, rats fed a meal with potassium, when compared with rats given a potassium-free meal, were better able to excrete a potassium load several hours later, leading to a lesser rise in the plasma potassium concentration after the second potassium load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/7\">",
"     7",
"    </a>",
"    ]. The net effect is that adapted animals excrete more potassium at a given plasma potassium concentration than animals that have not adapted (",
"    <a class=\"graphic graphic_figure graphicRef67129 \" href=\"mobipreview.htm?17/18/17709\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The efficacy of potassium adaptation in humans was demonstrated in a study evaluating the response of healthy adults to increasing potassium intake from 100 to 400",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/8\">",
"     8",
"    </a>",
"    ]. Urinary potassium excretion rose to equal intake by the end of the second day, an effect that was accompanied by an elevation in both aldosterone secretion and the plasma potassium concentration (from 3.8 to 4.8",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"     figure 3",
"    </a>",
"    ). At day 20, urinary potassium excretion continued to match the high level of intake, but plasma aldosterone levels had returned to near baseline, and the plasma potassium concentration had fallen to 4.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The increased efficiency of potassium excretion with potassium adaptation appears to be mediated by two changes that occur in the potassium-secreting principal cells in the connecting segment and cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An aldosterone-independent increase in the density and activity of apical secretory potassium channels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/2,9,10\">",
"       2,9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased Na-K-ATPase activity, which enhances potassium uptake into the cell across the basolateral (peritubular) membrane, which increases the size of the potassium secretory pool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367758506\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations lead to the following conclusions concerning the causes of hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing potassium intake alone is",
"      <strong>",
"       not",
"      </strong>",
"      a common cause of hyperkalemia unless it occurs acutely. Acute hyperkalemia can rarely be induced (primarily in infants because of their small size) by the administration of potassium penicillin as an intravenous bolus, the accidental ingestion of a potassium-containing salt substitute, or the use of stored blood for exchange transfusions. In addition, moderate increases in potassium intake can be an important contributor to the development of hyperkalemia in patients with impaired potassium excretion due, for example, to hypoaldosteronism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Reduced urinary potassium excretion'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The net release of potassium from the cells (due to enhanced release or decreased entry) can, if large enough (eg, increased tissue breakdown), cause a transient elevation in the serum potassium concentration. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Increased potassium release from cells'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Persistent hyperkalemia requires",
"      <strong>",
"       impaired urinary potassium excretion",
"      </strong>",
"      . In view of the factors described above, this is generally associated with a reduction in aldosterone secretion or responsiveness, acute or chronic kidney disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished delivery of sodium and water to the distal potassium secretory site. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Reduced urinary potassium excretion'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the causes of hyperkalemia are discussed in detail elsewhere and will only be listed below (",
"    <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCREASED POTASSIUM RELEASE FROM CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pseudohyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohyperkalemia refers to those conditions in which the elevation in the measured serum potassium concentration is usually due to potassium movement out of the cells during or after the blood specimen has been drawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/13\">",
"     13",
"    </a>",
"    ]. The possible presence of pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no electrocardiographic manifestations of hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156422759\">",
"    <span class=\"h3\">",
"     Technique of blood drawing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypokalemia can be seen in a variety of settings. The most common causes are related to the technique of blood drawing and can involve one or both of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical trauma during venipuncture can result in the release of potassium from red cells and a characteristic reddish tint of the serum due to the concomitant release of hemoglobin.",
"      <br/>",
"      <br/>",
"      Red serum can also represent severe intravascular hemolysis rather than a hemolyzed specimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/14\">",
"       14",
"      </a>",
"      ]. When intravascular hemolysis is present, the measured serum potassium may represent the true circulating value.",
"     </li>",
"     <li>",
"      Potassium moves out of muscle cells with exercise. As a result, repeated fist clenching during blood drawing can acutely raise the serum potassium concentration by more than 1 to 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in that forearm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Exercise'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these settings, venipuncture without a tourniquet, repeated fist clenching, or trauma will demonstrate the true serum potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/16\">",
"     16",
"    </a>",
"    ]. If a tourniquet is required, the tourniquet should be released after the needle has entered the vein, followed by waiting for",
"    <strong>",
"     one to two minutes",
"    </strong>",
"    before drawing the blood sample.",
"   </p>",
"   <p>",
"    Less common causes of an increase in serum potassium related to collection and storage include cooling of the sample and specimen deterioration because of prolonged length of storage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/13,17\">",
"     13,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156422766\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other settings in which pseudohyperkalemia can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potassium moves out of platelets after clotting has occurred. Thus, the serum potassium concentration normally exceeds the true value in plasma by 0.1 to 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/18\">",
"       18",
"      </a>",
"      ]. Although this difference in normal individuals is not clinically important, the increase in the measured serum potassium concentration can be much greater in normokalemic patients with thrombocytosis, rising by approximately 0.15",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      elevation in the platelet count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/18\">",
"       18",
"      </a>",
"      ]. In one study, hyperkalemia in a serum sample occurred in 34 percent of patients with a platelet count above",
"      <span class=\"nowrap\">",
"       500,000/microL",
"      </span>",
"      compared with 9 percent of patients with a platelet count less than",
"      <span class=\"nowrap\">",
"       250,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/18\">",
"       18",
"      </a>",
"      ]. The concentration of potassium in plasma (obtained by centrifugation of heparinized, unclotted blood) was normal.",
"      <br/>",
"      <br/>",
"      A similar phenomenon has been reported in acute myeloid leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/19\">",
"       19",
"      </a>",
"      ]. However,",
"      <strong>",
"       hypokalemia",
"      </strong>",
"      is more common in this disorder, due to movement of potassium into rapidly proliferating cells after the blood has been drawn (pseudohypokalemia) or to renal potassium wasting (true hypokalemia). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14168?source=see_link&amp;anchor=H896838#H896838\">",
"       \"Overview of the complications of acute myeloid leukemia\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High white blood cell counts",
"      <span class=\"nowrap\">",
"       (&gt;120,000/microL)",
"      </span>",
"      caused by chronic lymphocytic leukemia can lead to falsely elevated potassium concentrations due to cell fragility. Unlike thrombocytosis, this form of pseudohyperkalemia occurs in",
"      <strong>",
"       both",
"      </strong>",
"      serum and plasma samples and may be more prominent when blood is sampled in heparinized tubes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/20\">",
"       20",
"      </a>",
"      ]. Centrifugation of a heparinized tube causes in vitro cell destruction and release of potassium as these cells are freely suspended in plasma.",
"      <br/>",
"      <br/>",
"      Accurate assessment of the potassium concentration in this setting can be achieved by allowing clotting to separate serum (plasma without the clotting factors) from cells",
"      <strong>",
"       before",
"      </strong>",
"      centrifugation. The fibrin clot entraps and protects fragile leukemic cells, minimizing cell lysis.",
"      <br/>",
"      <br/>",
"      Pseudohyperkalemia in patients with very high white blood cell counts due to leukemia or lymphoma has also been reported after mechanical disruption of white blood cells during transport of blood samples via pneumatic tube systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Potassium can move out of red cells after the specimen is collected in patients with hereditary (familial) forms of pseudohyperkalemia, which are caused by an increase in the passive potassium permeability of erythrocytes. Pseudohyperkalemia may be the only manifestation of the disorder, or it may be accompanied by abnormal red cell morphology (eg, stomatocytosis), varying degrees of hemolysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perinatal edema in specific kindreds. This genetically heterogeneous condition is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=see_link&amp;anchor=H8#H8\">",
"       \"Stomatocytosis\", section on 'Familial pseudohyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with metabolic acidosis other than organic acidosis due to lactic acidosis or ketoacidosis, buffering of excess hydrogen ions in the cells leads to potassium movement into the extracellular fluid, a transcellular shift that is obligated in part by the need to maintain electroneutrality (",
"    <a class=\"graphic graphic_figure graphicRef68866 \" href=\"mobipreview.htm?9/25/9628\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=see_link&amp;anchor=H3#H3\">",
"     \"Potassium balance in acid-base disorders\", section on 'Metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this shift will tend to raise the plasma potassium concentration, some patients have concurrent potassium losses due to gastrointestinal disease (eg, diarrhea) or increased urinary losses (eg, renal tubular acidosis). In these settings, the measured serum potassium concentration may be normal or reduced despite the presence of metabolic acidosis. However, the plasma potassium will be higher than it would have been if the same degree of potassium loss had occurred in the absence of metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446278642\">",
"    <span class=\"h3\">",
"     Smaller effect in lactic acidosis or ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above finding, hyperkalemia due to an acidosis-induced shift of potassium from the cells into the extracellular fluid does",
"    <strong>",
"     not",
"    </strong>",
"    occur in the organic acidoses lactic acidosis and ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. A possible contributory factor in both disorders is the ability of the organic anion and the hydrogen ion to enter into the cell via a sodium-organic anion cotransporter. The transport mechanisms involved and how they minimize potassium movement out of the cells are discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described below, the development of hyperkalemia in patients with diabetic ketoacidosis is primarily due to insulin deficiency and hyperosmolality, not acidemia. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Insulin deficiency, hyperglycemia, and hyperosmolality'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129571552\">",
"    <span class=\"h3\">",
"     Smaller effect in respiratory acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia due to respiratory acidosis is not a common clinical problem. The effect of respiratory acidosis on the plasma potassium concentration has been primarily evaluated in acute rather than chronic respiratory acidosis. In a review of the available human data, respiratory acidosis produced",
"    <strong>",
"     no",
"    </strong>",
"    significant effect on the plasma potassium, although the degree of acidemia in the reviewed studies was usually mild (fall in plasma pH about 0.1); in addition, the increase in plasma potassium for a given reduction in pH was smaller when the fall in pH was induced by respiratory as compared with metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/23\">",
"     23",
"    </a>",
"    ]. The effect of respiratory acidosis on the plasma potassium is greater with more severe acidosis and with a longer duration of acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/27\">",
"     27",
"    </a>",
"    ]. The mechanisms responsible for the lesser increase in plasma potassium in respiratory acidosis compared with metabolic acidosis are not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in animal models of acute respiratory acidosis have shown variable increases in plasma potassium with the severity and duration of the acidosis. The following illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in dogs, severe acute respiratory acidosis (a decrease in mean plasma pH from 7.4 to 7) had no effect on the plasma potassium at ten minutes but, at two and six hours, the plasma potassium had increased from 4 to 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (approximately 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per 0.1 reduction in plasma pH) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/28\">",
"       28",
"      </a>",
"      ]. The increase in plasma potassium was due to potassium movement out of cells and was approximately twice as large when the ureters were ligated, suggesting a role for urinary excretion of some of the excess potassium.",
"     </li>",
"     <li>",
"      As might be expected, other studies in dogs with less severe acute respiratory acidosis found no [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/29\">",
"       29",
"      </a>",
"      ] or only small elevations in the plasma potassium concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Insulin deficiency, hyperglycemia, and hyperosmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin promotes potassium entry",
"    <strong>",
"     into",
"    </strong>",
"    cells. Thus, the ingestion of glucose (which stimulates endogenous insulin secretion) minimizes the rise in the serum potassium concentration induced by concurrent potassium intake (",
"    <a class=\"graphic graphic_figure graphicRef52424 \" href=\"mobipreview.htm?9/46/9966\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/31\">",
"     31",
"    </a>",
"    ], while glucose ingestion alone in patients without diabetes modestly lowers the serum potassium (",
"    <a class=\"graphic graphic_figure graphicRef64207 \" href=\"mobipreview.htm?13/22/13677\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings are different in uncontrolled diabetes mellitus. In this setting, the combination of insulin deficiency (either impaired secretion or insulin resistance) and hyperosmolality induced by hyperglycemia frequently leads to hyperkalemia even though there may be marked potassium depletion due to urinary losses caused by the osmotic diuresis (",
"    <a class=\"graphic graphic_figure graphicRef64207 \" href=\"mobipreview.htm?13/22/13677\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in plasma osmolality results in osmotic water movement from the cells into the extracellular fluid. This is accompanied by potassium movement out of the cells by two proposed mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of cell water raises the cell potassium concentration, thereby creating a favorable gradient for passive potassium exit through potassium channels in the cell membrane.",
"     </li>",
"     <li>",
"      The friction forces between solvent (water) and solute can result in potassium being carried along with water through the water pores in the cell membrane. This phenomenon of solvent drag is independent of the electrochemical gradient for potassium diffusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90534304\">",
"    <span class=\"h3\">",
"     Causes other than diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders other than diabetes mellitus have been associated with hyperkalemia due to insulin deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperosmolality. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin levels fall in response to therapy with somatostatin or the somatostatin agonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , and can lead to elevations in serum potassium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. The magnitude of this effect varies with the clinical setting. In one study, for example, the mean increase in serum potassium was 0.5 to 0.6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in normal individuals and patients with type 2 diabetes; in contrast, there was no change in serum potassium in patients with type 1 diabetes since they make little or no insulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/35\">",
"       35",
"      </a>",
"      ]. The effect of somatostatin or octreotide is much greater in patients with end-stage renal disease requiring dialysis in whom the serum potassium can rise above 7",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fasting is associated with an appropriate reduction in insulin levels that can lead to an increase in plasma potassium. This may be a particular problem in dialysis patients. (See",
"      <a class=\"local\" href=\"#H270425989\">",
"       'Acute and chronic kidney disease'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The risk of hyperkalemia during preoperative fasting can be minimized by the administration of insulin and glucose in patients with diabetes, or glucose alone in patients without diabetes (",
"      <a class=\"graphic graphic_figure graphicRef64207 \" href=\"mobipreview.htm?13/22/13677\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to hyperglycemia induced by insulin deficiency, hyperkalemia induced by hyperosmolality has also been described with hypernatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/39\">",
"       39",
"      </a>",
"      ], sucrose contained in intravenous immune globulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/40\">",
"       40",
"      </a>",
"      ], radiocontrast media [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/41\">",
"       41",
"      </a>",
"      ], and the administration of hypertonic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/42\">",
"       42",
"      </a>",
"      ]. Most of the reported patients had renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of mannitol therapy\", section on 'Volume expansion, hyponatremia, hyperkalemia, and metabolic acidosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased tissue catabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any cause of increased tissue breakdown leads to the release of intracellular potassium into the extracellular fluid. Hyperkalemia can occur in this setting, particularly if renal failure is also present. Clinical examples include trauma (including non-crush trauma), the administration of cytotoxic or radiation therapy to patients with lymphoma or leukemia (the tumor lysis syndrome), and severe accidental hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15369?source=see_link&amp;anchor=H7#H7\">",
"     \"Crush-related acute kidney injury (acute renal failure)\", section on 'Biochemical abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link&amp;anchor=H491877#H491877\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=see_link&amp;anchor=H3#H3\">",
"     \"Accidental hypothermia in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased beta-2-adrenergic activity drives potassium into the cells and lowers the serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers interfere with the beta-2-adrenergic facilitation of potassium uptake by the cells, particularly after a potassium load (",
"    <a class=\"graphic graphic_figure graphicRef62538 \" href=\"mobipreview.htm?29/51/30525\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. An increase in serum potassium is primarily seen with nonselective beta blockers (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ). In contrast, beta-1-selective blockers such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    have little effect on serum potassium since beta-2 receptor activity remains intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rise in serum potassium with nonselective beta blocker therapy is usually less than 0.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    True hyperkalemia is rare unless there is a large potassium load, marked exercise (as described in the next section), or an additional defect in potassium handling that prevents excretion of the excess extracellular potassium, such as hypoaldosteronism or renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. In one report, for example, three renal transplant recipients developed severe hyperkalemia after the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    for postoperative hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium is normally released from muscle cells during exercise. The increase in plasma potassium is rarely important clinically, with the one major exception that fist clenching during blood drawing can interfere with accurate assessment of the serum potassium concentration. Repeated fist clenching during blood drawing can acutely raise the serum potassium concentration by more than 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in that forearm, thereby representing a form of pseudohyperkalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pseudohyperkalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The increase in plasma potassium during exercise may be mediated by two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A delay between potassium exit from the cells during depolarization and subsequent reuptake into the cells via the Na-K-ATPase pump.",
"     </li>",
"     <li>",
"      With marked exercise, an increased number of open potassium channels in the cell membrane. These channels are inhibited by ATP, an effect that is removed by the exercise-induced decline in ATP levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The release of potassium during exercise may have a physiologically important role. The",
"    <strong>",
"     local",
"    </strong>",
"    increase in potassium concentration has a vasodilator effect, thereby increasing blood flow and energy delivery to the exercising muscle.",
"   </p>",
"   <p>",
"    The degree of elevation in the plasma potassium concentration in the",
"    <strong>",
"     systemic circulation",
"    </strong>",
"    is less pronounced and varies directly with the degree of exercise: 0.3 to 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with slow walking; 0.7 to 1.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with moderate exertion (including prolonged aerobic exercise with marathon running); and as much as 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    following exercise to exhaustion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/49,51-54\">",
"     49,51-54",
"    </a>",
"    ], which may be associated with both ECG changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/53\">",
"     53",
"    </a>",
"    ] and lactic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak increase in plasma potassium during exercise is",
"    <strong>",
"     less",
"    </strong>",
"    pronounced with prior physical conditioning (perhaps due to increased Na-K-ATPase activity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/55\">",
"     55",
"    </a>",
"    ] and",
"    <strong>",
"     more",
"    </strong>",
"    pronounced in patients treated with nonselective beta blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/51\">",
"     51",
"    </a>",
"    ] or those with end-stage renal disease even though there is often a lesser degree of attained exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rise in plasma potassium concentration induced by exercise is reversed after several minutes of rest and is typically associated with a mild rebound hypokalemia (averaging 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below the baseline level) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. It has been suggested that the changes in plasma potassium might be arrhythmogenic in susceptible patients, such as those with angina pectoris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperkalemic periodic paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemic periodic paralysis is an autosomal dominant disorder in which episodes of weakness or paralysis are usually precipitated by cold exposure, rest after exercise, fasting, or the ingestion of small amounts of potassium. The most common abnormality in hyperkalemic periodic paralysis is a point mutation in the gene for the alpha subunit of the skeletal muscle cell sodium channel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyperkalemic periodic paralysis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare causes of hyperkalemia due to translocation of potassium from the cells into the extracellular fluid include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digitalis overdose, due to dose-dependent inhibition of the Na-K-ATPase pump [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/57\">",
"       57",
"      </a>",
"      ]. Hyperkalemia can also occur after poisoning with structurally related digitalis glycosides, as may occur after ingestion of the plants, common oleander or yellow oleander [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/58\">",
"       58",
"      </a>",
"      ], or extracts of the cane toad, Bufo marinus (bufadienolides) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=see_link&amp;anchor=H11#H11\">",
"       \"Digitalis (cardiac glycoside) poisoning\", section on 'Electrolyte abnormalities'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H7184730#H7184730\">",
"       \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Cardiac glycosides (eg, oleander, foxglove)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red cell transfusion due to leakage of potassium out of the red cells during storage. Hyperkalemia primarily occurs in infants and with massive transfusions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H9#H9\">",
"       \"Use of red blood cells for transfusion\", section on 'Potassium leakage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      to patients with burns, extensive trauma, prolonged immobilization, chronic infection, or neuromuscular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. Acetylcholine receptors are normally concentrated within the neuromuscular junction, and the efflux of intracellular potassium caused by depolarization of these receptors is confined to this space. Hyperkalemia occurs when succinylcholine is given under conditions that cause upregulation and widespread distribution of acetylcholine receptors throughout the entire muscle membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of arginine hydrochloride, which is metabolized in part to hydrochloric acid and has been used to treat refractory metabolic alkalosis. The entry of cationic arginine into the cells presumably obligates potassium exit to maintain electroneutrality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/63\">",
"       63",
"      </a>",
"      ]. The drug,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      , can cause hyperkalemia by the same mechanism since it is structurally similar to arginine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=see_link&amp;anchor=H22245432#H22245432\">",
"       \"Treatment of metabolic alkalosis\", section on 'Hydrochloric acid regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of drugs that activate ATP-dependent potassium channels in cell membranes, such as calcineurin inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      , and several volatile anesthetics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"       isoflurane",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/66\">",
"       66",
"      </a>",
"      ]. As described elsewhere, other mechanisms are also involved in calcineurin inhibitor-induced hyperkalemia, including hyporeninemic hypoaldosteronism and inhibition of the luminal potassium channel through which potassium is secreted (",
"      <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduced aldosterone secretion'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link&amp;anchor=H9#H9\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Hyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REDUCED URINARY POTASSIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary potassium excretion is primarily mediated by potassium secretion in the principal cells in the two segments that follow the distal tubule: the connecting segment and cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ). Three major factors are required for adequate potassium secretion at these sites:",
"    <strong>",
"     adequate",
"    </strong>",
"    <strong>",
"     aldosterone secretion",
"    </strong>",
"    ,",
"    <strong>",
"     adequate responsiveness to aldosterone",
"    </strong>",
"    , and",
"    <strong>",
"     adequate distal sodium and water delivery",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/67\">",
"     67",
"    </a>",
"    ]. The widely used term, hypoaldosteronism, applies to both reduced aldosterone secretion and reduced response to aldosterone. (See",
"    <a class=\"local\" href=\"#H7397120\">",
"     'Brief review of potassium physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The four major causes of hyperkalemia due to reduced urinary potassium secretion are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced aldosterone secretion",
"     </li>",
"     <li>",
"      Reduced response to aldosterone (aldosterone resistance)",
"     </li>",
"     <li>",
"      Reduced distal sodium and water delivery as occurs in effective arterial blood volume depletion",
"     </li>",
"     <li>",
"      Acute and chronic kidney disease in which one or more of the above factors are present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other mechanisms for reduced urinary potassium secretion have rarely been described. (See",
"    <a class=\"local\" href=\"#H270419983\">",
"     'Other mechanisms of impaired potassium secretion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to directly causing hyperkalemia, impaired urinary potassium excretion can also contribute to hyperkalemia induced by potassium release from the cells (",
"    <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Increased potassium release from cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reduced aldosterone secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any cause of decreased aldosterone release, such as that induced by hyporeninemic hypoaldosteronism or certain drugs, can diminish the efficiency of potassium secretion and lead to hyperkalemia and metabolic acidosis (called type 4 renal tubular acidosis) (",
"    <a class=\"graphic graphic_table graphicRef82440 \" href=\"mobipreview.htm?41/0/41995\">",
"     table 2",
"    </a>",
"    ). Drugs commonly implicated include angiotensin inhibitors, nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperkalemia is a common problem in patients treated with the calcineurin inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . These drugs can induce hyporeninemic hypoaldosteronism and can also interfere with the effect of aldosterone on the potassium-secreting cells in the connecting segment and cortical collecting tubule. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rise in plasma potassium concentration induced by reductions in aldosterone secretion or aldosterone response directly stimulates potassium secretion, partially overcoming the relative absence of aldosterone. The net effect is that the rise in the plasma potassium concentration is generally small in patients with normal renal function but can be clinically important in the presence of underlying renal insufficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other causes of hyperkalemia (",
"    <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774689278\">",
"    <span class=\"h2\">",
"     Reduced response to aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of causes of hyperkalemia that are due to a reduced response to aldosterone, also called aldosterone or mineralocorticoid resistance. The most common are the administration of potassium-sparing diuretics and acute and chronic kidney disease in which other factors may also contribute. (See",
"    <a class=\"local\" href=\"#H270425989\">",
"     'Acute and chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774689287\">",
"    <span class=\"h3\">",
"     Potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of medications impair renal potassium secretion despite normal or high levels of aldosterone: aldosterone antagonists that compete with aldosterone for receptor sites (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ), and drugs that directly block the sodium channels in the apical (luminal) membrane of the principal cells in the collecting tubule (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Voltage-dependent renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with distal renal tubular acidosis (RTA), the primary defect is impaired sodium reabsorption in the principal cells in the two segments that follow the distal tubule (the connecting segment and the cortical collecting tubule). The movement of sodium from the lumen into the principal cells makes the lumen electronegative, thereby promoting the secretion of both hydrogen ions and potassium (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ). In contrast, an impairment in sodium reabsorption will reduce both hydrogen and potassium secretion, which will promote the development of metabolic acidosis and hyperkalemia. This disorder, which has been called voltage-dependent RTA, has been associated with urinary tract obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/68\">",
"     68",
"    </a>",
"    ], lupus nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/69\">",
"     69",
"    </a>",
"    ], sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/70\">",
"     70",
"    </a>",
"    ], and renal amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Diminished sodium reabsorption in the adjacent principal cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A somewhat similar defect is induced by hypoaldosteronism since aldosterone normally increases the number of open sodium channels in the luminal membrane. In contrast to hypoaldosteronism, voltage-dependent RTA is associated with normal or even high aldosterone levels and an inability to normally acidify the urine, as the urine pH is above 5.5. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Reduced aldosterone secretion'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270421097\">",
"    <span class=\"h3\">",
"     Pseudohypoaldosteronism type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoaldosteronism type 1 is a rare hereditary disorder that is characterized by aldosterone resistance. The autosomal recessive form affects the collecting tubule sodium channel (ENaC) (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ), and the autosomal dominant form in most patients affects the mineralocorticoid receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H654524127#H654524127\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Pseudohypoaldosteronism type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270420126\">",
"    <span class=\"h2\">",
"     Reduced distal sodium and water delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the presence of normal or increased plasma aldosterone levels, potassium secretion and therefore urinary potassium excretion can be impaired if there is a substantial reduction in sodium and water delivery to the potassium secretory sites in the distal nephron (connecting segment and cortical collecting tubule). As an example, potassium secretion by perfused rabbit cortical collecting ducts is dramatically inhibited at a luminal sodium concentration of 8",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and essentially stops at a luminal sodium concentration of 0",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/72\">",
"     72",
"    </a>",
"    ]. Dietary sodium intake also influences potassium excretion; the potassium secretory capacity is enhanced by excess sodium intake and reduced by sodium restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common cause of reduced distal sodium and water delivery is effective arterial blood volume depletion, which may be accompanied by other factors that promote the development of hyperkalemia. Measurement of urinary sodium concentration, combined with a therapeutic response to saline hydration, can help confirm this pathophysiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270420133\">",
"    <span class=\"h3\">",
"     Effective arterial blood volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective arterial blood volume (also called effective circulating volume) refers to the arterial blood volume that is effectively perfusing the tissues. Effective arterial blood volume depletion includes any cause of true volume depletion (eg, gastrointestinal or renal losses) as well as heart failure and cirrhosis in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link&amp;anchor=H37261267#H37261267\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Effective arterial blood volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any cause of effective arterial blood volume depletion can lead sequentially to decreased delivery of sodium and water to the sites of potassium secretion in the distal nephron (connecting segment and cortical collecting tubule), impaired potassium secretion into the tubular lumen, and hyperkalemia (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7397120\">",
"     'Brief review of potassium physiology'",
"    </a>",
"    above.) However, the effect of impaired potassium secretion can be minimized or overcome, possibly resulting in hypokalemia, if there are concurrent potassium losses, as in patients with vomiting or diarrhea, or those treated with diuretic therapy.",
"   </p>",
"   <p>",
"    In addition to decreased distal delivery of sodium and water, other potentially important contributing factors to hyperkalemia in patients with heart failure and cirrhosis include angiotensin inhibitor therapy in heart failure (but not cirrhosis) and aldosterone antagonists in both heart failure and cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10069?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal effects of ACE inhibitors in heart failure\", section on 'Hyperkalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Risk of hyperkalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H11163054#H11163054\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Avoidance of angiotensin inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270425989\">",
"    <span class=\"h2\">",
"     Acute and chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is a common complication of acute and chronic kidney disease. In patients with acute kidney injury, hyperkalemia is most prevalent in oliguric patients who also have increased potassium release from cells due, for example, to rhabdomyolysis or tumor lysis syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30425?source=see_link&amp;anchor=H6570030#H6570030\">",
"     \"Overview of the management of acute kidney injury (acute renal failure)\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with chronic kidney disease, the ability to excrete potassium at near-normal levels without the development of hyperkalemia generally persists as long as both the secretion of and responsiveness to aldosterone are intact and distal delivery of sodium and water are maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/76\">",
"     76",
"    </a>",
"    ]. Hyperkalemia is most commonly seen in patients who are oliguric or have an additional problem such as a high-potassium diet, increased tissue breakdown, reduced aldosterone secretion or responsiveness, or fasting in dialysis patients which may both lower insulin levels and cause resistance to beta-adrenergic stimulation of potassium uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/33,76-78\">",
"     33,76-78",
"    </a>",
"    ]. In dialysis patients who fasted prior to surgery, the administration of insulin and glucose or, to a lesser degree, glucose alone in nondiabetic patients can minimize the elevation in the serum potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Insulin deficiency, hyperglycemia, and hyperosmolality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Impaired cell uptake of potassium also contributes to the development of hyperkalemia in advanced renal failure (",
"    <a class=\"graphic graphic_figure graphicRef52424 \" href=\"mobipreview.htm?9/46/9966\">",
"     figure 5",
"    </a>",
"    ). Diminished Na-K-ATPase activity may be particularly important in this setting. How this occurs is not clear, but retained uremic toxins may decrease the transcription of mRNA for the alpha1 isoform of the Na-K-ATPase pump in skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/77,79,80\">",
"     77,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270420140\">",
"    <span class=\"h2\">",
"     Multiple factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of multiple factors that impair potassium secretion can lead to more severe and possibly life-threatening hyperkalemia. One setting in which this can occur is in patients with moderate to severe heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. These patients often have reduced distal sodium and water delivery due to the associated renal hypoperfusion, relatively decreased aldosterone release (from treatment with angiotensin-converting enzyme [ACE] inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers [ARBs]), and reduced aldosterone effect (from treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Risk of hyperkalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Hyperkalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270419983\">",
"    <span class=\"h2\">",
"     Other mechanisms of impaired potassium secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the common mechanisms of hyperkalemia due to reduced urinary potassium excretion described above, there are other, less common causes of hyperkalemia in which urinary potassium excretion is impaired due to mechanisms not directly related to reduced secretion of or response to aldosterone or to reduced distal sodium and water delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Selective impairment in potassium secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with hyperkalemia have impaired urinary potassium excretion despite normal aldosterone release and normal distal sodium and water delivery. This seemingly selective impairment in potassium secretion, which does not respond to exogenous mineralocorticoid, has been described with lupus nephritis, acute transplant rejection, and sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. These patients do not have sodium wasting and have a normal antinatriuretic response to mineralocorticoids, indicating a selective potassium defect,",
"    <strong>",
"     not",
"    </strong>",
"    aldosterone resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In at least some cases, the potassium secretory defect may be due to interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A selective impairment in potassium secretion can also occur in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . One or more mechanisms involved in tubular potassium secretion may be impaired. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774690471\">",
"    <span class=\"h3\">",
"     Pseudohypoaldosteronism type 2 (Gordon's syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inherited syndrome of hyperkalemia, volume expansion, hypertension, and otherwise normal renal function has been called pseudohypoaldosteronism type 2, Gordon's syndrome, or familial hyperkalemic hypertension. The reduction in aldosterone secretion represents an",
"    <strong>",
"     appropriate",
"    </strong>",
"    response to volume expansion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ureterojejunostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rise in the serum potassium concentration can occur in patients with a urinary diversion procedure in which the ureters are inserted into the jejunum (called a ureterojejunostomy). Hyperkalemia in this setting is presumably due to absorption of urinary potassium by the jejunum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link&amp;anchor=H11#H11\">",
"     \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\", section on 'Changes in serum potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156422221\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient with hyperkalemia usually begins with a careful history, evaluation for clinical manifestations of hyperkalemia such as muscle weakness and characteristic changes on the electrocardiogram, and laboratory testing for the causes of hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156422773\">",
"    <span class=\"h2\">",
"     Exclude pseudohyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohyperkalemia, which is discussed above, refers to those conditions in which the elevation in the measured serum potassium concentration is due to potassium movement out of the cells during or after the blood specimen has been drawn. It is usually related to the technique of blood drawing, but it can also occur in patients with marked elevations in platelet or white blood cell counts. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pseudohyperkalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no clinical or electrocardiographic manifestations of hyperkalemia. One clue to the possible presence of pseudohyperkalemia is wide variability in repeated measurements of the serum potassium concentration (eg, from 5 to 6.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    often including some normal values). In contrast, patients with normokalemia and those with true chronic hyperkalemia, most often due to hypoaldosteronism or chronic kidney disease, tend to have stable values over the short term, although higher values can occur over time if there is progression of the underlying disease.",
"   </p>",
"   <p>",
"    If an artifact of blood drawing is suspected or there is no apparent cause for hyperkalemia, venipuncture without a tourniquet, repeated fist clenching, or trauma will demonstrate the true serum potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/16\">",
"     16",
"    </a>",
"    ]. If a tourniquet is required, the tourniquet should be released after the needle has entered the vein, followed by waiting for one to two minutes before drawing the blood sample. The diagnosis of pseudohyperkalemia in patients with thrombocytosis or markedly elevated white blood cell counts is described above. (See",
"    <a class=\"local\" href=\"#H156422766\">",
"     'Other causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156422795\">",
"    <span class=\"h2\">",
"     Acute rise in serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of pseudohyperkalemia or recent potassium administration, an acute rise in serum potassium is often due to increased release of potassium from the cells, and the cause is identified from the history and laboratory data. Increased tissue catabolism is a classic example that is most often due to trauma or cytotoxic or radiation therapy in patients with lymphoma or leukemia (the tumor lysis syndrome). Diabetic ketoacidosis is another cause of an acute rise in serum potassium, a change that is more pronounced if kidney function is impaired. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Increased tissue catabolism'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Insulin deficiency, hyperglycemia, and hyperosmolality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Metabolic acidosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Increasing potassium intake is",
"    <strong>",
"     not",
"    </strong>",
"    a major cause of hyperkalemia in individuals without another risk factor such as reduced aldosterone secretion or responsiveness or acute or chronic kidney disease. In healthy adults, raising potassium intake from a normal value of 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    to a much higher value of 400",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    only produces a modest elevation in serum potassium from 3.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline to 4.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at the end of day 2 and 4.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at day 20 (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/8\">",
"     8",
"    </a>",
"    ]. Urinary potassium excretion increases to the level of intake by the end of the second day, an effect that is mediated by both the elevation in plasma potassium and increased secretion of aldosterone. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Potassium adaptation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873885\">",
"    <span class=\"h2\">",
"     Persistent hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the ability of healthy individuals to handle large potassium loads with only a small rise in serum potassium (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/8\">",
"     8",
"    </a>",
"    ], the most common causes of persistent hyperkalemia are associated with impaired urinary potassium excretion due to reduced secretion of or response to aldosterone, acute or chronic kidney disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effective arterial blood volume depletion. Effective arterial blood volume depletion may be due to true volume depletion or to heart failure or cirrhosis, in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively (",
"    <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Reduced urinary potassium excretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Administration of angiotensin inhibitors and aldosterone antagonists in patients with heart failure can contribute to the development of hyperkalemia but can also improve patient outcomes. Limiting potassium intake and the use of loop diuretics may minimize the degree of hyperkalemia and allow these potentially life-saving therapies to be continued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'ACE inhibitors or beta blockers first'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Aldosterone antagonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of hyperkalemia in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249933270\">",
"    <span class=\"h3\">",
"     Urinary potassium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of 24-hour urinary potassium excretion is of",
"    <strong>",
"     limited utility",
"    </strong>",
"    in patients with persistent",
"    <strong>",
"     stable",
"    </strong>",
"    hyperkalemia because urinary potassium excretion is primarily determined by and roughly equal to potassium intake. These patients have an impairment in urinary potassium excretion since a higher-than-normal plasma potassium concentration is required to excrete the daily potassium load.",
"   </p>",
"   <p>",
"    Although uncommon, 24-hour urinary potassium excretion above 80 to 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (normal potassium intake) suggests that increased potassium intake (as with ingestion of a salt substitute) may be contributing to the hyperkalemia. However, as noted above, increasing potassium intake alone is not sufficient in healthy adults. In this setting, raising potassium intake from 100 to 400",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    only increases the serum potassium from 3.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline to 4.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at the end of day 2 and 4.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    by day 20, a time at which intake and output are again equal (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Potassium adaptation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249933336\">",
"    <span class=\"h3\">",
"     Transtubular potassium gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;It would be desirable to assess the degree of aldosterone activity in patients with hyperkalemia by estimating the tubular fluid potassium concentration at the most distal site of potassium secretion in the cortical collecting tubule. Although this measurement cannot be made in humans, it was proposed that the potassium concentration at this site could be estimated clinically from calculation of the transtubular potassium gradient (TTKG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a later publication, the authors of the original studies found that the assumptions underlying the TTKG were",
"    <strong>",
"     not valid",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/5/33882/abstract/93\">",
"     93",
"    </a>",
"    ]. It was concluded that the TTKG was not a reliable test for the diagnosis of hyperkalemia. We recommend",
"    <strong>",
"     not",
"    </strong>",
"    using the TTKG to evaluate patients with hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249933454\">",
"    <span class=\"h3\">",
"     Diagnosis of hypoaldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hyperkalemia in whom the etiology has not been identified should be evaluated for the presence and cause of hypoaldosteronism. This disorder can result from reduced aldosterone secretion or from aldosterone resistance, which most often occurs in patients treated with potassium-sparing diuretics and can be one of several factors that can contribute to hyperkalemia in acute and chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Reduced aldosterone secretion'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H774689278\">",
"     'Reduced response to aldosterone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to the diagnosis of hypoaldosteronism is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H3640046#H3640046\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Diagnosis of hypoaldosteronism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/34/15906?source=see_link\">",
"       \"Patient information: Hyperkalemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783293332\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of a potassium load leads initially to the uptake of most of the excess potassium by cells in muscle and the liver, a process that is facilitated by insulin and the beta-2-adrenergic receptors, both of which increase the activity of Na-K-ATPase pumps in the cell membrane. Some of the ingested potassium remains in the extracellular fluid, producing a mild elevation in the plasma potassium concentration. The increase in plasma potassium stimulates the secretion of aldosterone, which enhances both sodium reabsorption and potassium secretion by principal cells (",
"      <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7397120\">",
"       'Brief review of potassium physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing potassium intake alone is",
"      <strong>",
"       not",
"      </strong>",
"      a common cause of hyperkalemia unless it occurs acutely. The net release of potassium from the cells (due to enhanced release or decreased entry) can, if large enough (eg, increased tissue breakdown), cause a transient elevation in the serum potassium concentration. Persistent hyperkalemia requires",
"      <strong>",
"       impaired urinary potassium excretion",
"      </strong>",
"      . This is generally associated with a reduction in aldosterone secretion or responsiveness, acute or chronic kidney disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished delivery of sodium and water to the distal potassium secretory site (",
"      <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7397120\">",
"       'Brief review of potassium physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following are causes of hyperkalemia due to increased potassium release from cells (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Increased potassium release from cells'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pseudohyperkalemia &ndash; Pseudohyperkalemia includes those conditions in which the elevation in the measured serum potassium concentration is due to potassium movement out of the cells during or after the blood specimen has been drawn. The most common is mechanical trauma during venipuncture, which can result in the release of potassium from red cells and a characteristic reddish tint of the serum due to the concomitant release of hemoglobin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pseudohyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic acidosis &ndash; In patients with metabolic acidosis other than organic acidosis due to lactic acidosis or ketoacidosis, buffering of excess hydrogen ions in the cells leads to potassium movement into the extracellular fluid, a transcellular shift that is obligated in part by the need to maintain electroneutrality (",
"      <a class=\"graphic graphic_figure graphicRef68866 \" href=\"mobipreview.htm?9/25/9628\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin deficiency, hyperglycemia, and hyperosmolality &ndash; Insulin promotes potassium entry into cells, minimizing the rise in the serum potassium concentration induced by concurrent potassium intake (",
"      <a class=\"graphic graphic_figure graphicRef52424 \" href=\"mobipreview.htm?9/46/9966\">",
"       figure 5",
"      </a>",
"      ). In uncontrolled diabetes mellitus, the combination of insulin",
"      <span class=\"nowrap\">",
"       deficiency/resistance",
"      </span>",
"      and hyperosmolality induced by hyperglycemia frequently leads to hyperkalemia even though there may be marked potassium depletion due to urinary losses caused by the osmotic diuresis (",
"      <a class=\"graphic graphic_figure graphicRef64207 \" href=\"mobipreview.htm?13/22/13677\">",
"       figure 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Insulin deficiency, hyperglycemia, and hyperosmolality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased tissue catabolism &ndash; Any cause of increased tissue breakdown leads to the release of intracellular potassium into the extracellular fluid. Hyperkalemia can occur in this setting, particularly if renal failure is also present. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Increased tissue catabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blockers &ndash; Beta blockers interfere with the beta-2-adrenergic facilitation of potassium uptake by the cells, particularly after a potassium load (",
"      <a class=\"graphic graphic_figure graphicRef62538 \" href=\"mobipreview.htm?29/51/30525\">",
"       figure 7",
"      </a>",
"      ). An increase in serum potassium is primarily seen with nonselective beta blockers (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other causes of hyperkalemia due to increased potassium release from cells include exercise, hyperkalemic periodic paralysis, red cell transfusion, and various drugs including digitalis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Exercise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Hyperkalemic periodic paralysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The four major causes of hyperkalemia due to reduced urinary potassium secretion are (",
"      <a class=\"graphic graphic_table graphicRef58157 \" href=\"mobipreview.htm?9/15/9468\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Reduced urinary potassium excretion'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reduced aldosterone secretion &ndash; Any cause of decreased aldosterone release, such as that induced by hyporeninemic hypoaldosteronism or certain drugs, can diminish the efficiency of potassium secretion and lead to hyperkalemia and metabolic acidosis (called type 4 renal tubular acidosis) (",
"      <a class=\"graphic graphic_table graphicRef82440 \" href=\"mobipreview.htm?41/0/41995\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduced aldosterone secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced response to aldosterone (aldosterone resistance) &ndash; There are a number of causes of hyperkalemia that are due to a reduced response to aldosterone, also called aldosterone or mineralocorticoid resistance. The most common are the administration of potassium-sparing diuretics and acute and chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H774689278\">",
"       'Reduced response to aldosterone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced distal sodium and water delivery &ndash; Potassium secretion can be impaired if there is a substantial reduction in sodium and water delivery to the potassium secretory sites in the distal nephron (connecting segment and cortical collecting tubule). The most common cause is reduced effective arterial blood volume, including any cause of true volume depletion (eg, gastrointestinal or renal losses) as well as heart failure and cirrhosis in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively. (See",
"      <a class=\"local\" href=\"#H270420126\">",
"       'Reduced distal sodium and water delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute and chronic kidney disease &ndash; In patients with acute kidney injury, hyperkalemia is most prevalent in oliguric patients who also have increased potassium release from cells due, for example, to rhabdomyolysis or tumor lysis syndrome. In patients with chronic kidney disease, the ability to excrete dietary potassium without the development of hyperkalemia generally persists as long as both the secretion of and responsiveness to aldosterone are intact and distal delivery of sodium and water are maintained. However, moderate increases in potassium intake can be an important contributor to the development of hyperkalemia in patients with impaired potassium excretion due to renal insufficiency, particularly in combination with other predisposing factors (hyporeninemic hypoaldosteronism, angiotensin-converting enzyme [ACE] inhibitor therapy, etc). (See",
"      <a class=\"local\" href=\"#H270425989\">",
"       'Acute and chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes of impaired urinary potassium excretion include Gordon's syndrome and ureterojejunostomy. (See",
"    <a class=\"local\" href=\"#H270419983\">",
"     'Other mechanisms of impaired potassium secretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of the patient with hyperkalemia usually begins with a careful history, evaluation for clinical manifestations of hyperkalemia such as muscle weakness and characteristic changes on the electrocardiogram, and laboratory testing for the causes of hyperkalemia. (See",
"      <a class=\"local\" href=\"#H156422221\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no clinical or electrocardiographic manifestations of hyperkalemia. (See",
"      <a class=\"local\" href=\"#H156422773\">",
"       'Exclude pseudohyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of pseudohyperkalemia or recent potassium administration, an acute rise in serum potassium is often due to increased release of potassium from the cells, and the cause is identified from the history and laboratory data. (See",
"      <a class=\"local\" href=\"#H156422795\">",
"       'Acute rise in serum potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the ability of healthy individuals to handle large potassium loads with only a small rise in serum potassium (",
"      <a class=\"graphic graphic_figure graphicRef50808 \" href=\"mobipreview.htm?18/26/18862\">",
"       figure 3",
"      </a>",
"      ), the most common causes of persistent hyperkalemia are associated with impaired urinary potassium excretion due to reduced secretion of or response to aldosterone, acute or chronic kidney disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      effective arterial blood volume depletion. Measurement of 24-hour urinary potassium excretion is of",
"      <strong>",
"       limited utility",
"      </strong>",
"      in patients with persistent",
"      <strong>",
"       stable",
"      </strong>",
"      hyperkalemia, and the transtubular potassium gradient (TTKG) is",
"      <strong>",
"       not",
"      </strong>",
"      a reliable test for the diagnosis of hyperkalemia. Patients with persistent hyperkalemia in whom the etiology has not been identified should be evaluated for the presence and cause of hypoaldosteronism. (See",
"      <a class=\"local\" href=\"#H873885\">",
"       'Persistent hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/1\">",
"      Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/2\">",
"      Giebisch GH, Wang WH. Potassium transport--an update. J Nephrol 2010; 23 Suppl 16:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/3\">",
"      Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009; 71:381.",
"     </a>",
"    </li>",
"    <li>",
"     Mount DB, Zandi-Nejad K. Disorders of Potassium Balance. In: Brenner and Rector's The Kidney, 9th Ed, WB Saunders &amp; Company, Philadelphia 2011. p.640.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/5\">",
"      Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/6\">",
"      Bundgaard H, Schmidt TA, Larsen JS, Kjeldsen K. K+ supplementation increases muscle [Na+-K+-ATPase] and improves extrarenal K+ homeostasis in rats. J Appl Physiol 1997; 82:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/7\">",
"      Jackson CA. Rapid renal potassium adaptation in rats. Am J Physiol 1992; 263:F1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/8\">",
"      Rabelink TJ, Koomans HA, Hen&eacute; RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/9\">",
"      Palmer LG, Frindt G. Regulation of apical K channels in rat cortical collecting tubule during changes in dietary K intake. Am J Physiol 1999; 277:F805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/10\">",
"      Frindt G, Shah A, Edvinsson J, Palmer LG. Dietary K regulates ROMK channels in connecting tubule and cortical collecting duct of rat kidney. Am J Physiol Renal Physiol 2009; 296:F347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/11\">",
"      Garg LC, Narang N. Renal adaptation to potassium in the adrenalectomized rabbit. Role of distal tubular sodium-potassium adenosine triphosphatase. J Clin Invest 1985; 76:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/12\">",
"      Mujais SK. Renal memory after potassium adaptation: role of Na+-K+-ATPase. Am J Physiol 1988; 254:F845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/13\">",
"      Smellie WS. Spurious hyperkalaemia. BMJ 2007; 334:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/14\">",
"      Ismail A, Shingler W, Seneviratne J, Burrows G. In vitro and in vivo haemolysis and potassium measurement. BMJ 2005; 330:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/15\">",
"      Don BR, Sebastian A, Cheitlin M, et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/16\">",
"      Wiederkehr MR, Moe OW. Factitious hyperkalemia. Am J Kidney Dis 2000; 36:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/17\">",
"      Bailey IR, Thurlow VR. Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann Clin Biochem 2008; 45:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/18\">",
"      Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis 1988; 12:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/19\">",
"      Chumbley LC. Pseudohyperkalemia in acute myelocytic leukemia. JAMA 1970; 211:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/20\">",
"      Lee HK, Brough TJ, Curtis MB, et al. Pseudohyperkalemia--is serum or whole blood a better specimen type than plasma? Clin Chim Acta 2008; 396:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/21\">",
"      Chawla NR, Shapiro J, Sham RL. Pneumatic tube \"pseudo tumor lysis syndrome\" in chronic lymphocytic leukemia. Am J Hematol 2009; 84:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/22\">",
"      Kellerman PS, Thornbery JM. Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient. Am J Kidney Dis 2005; 46:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/23\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/24\">",
"      Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 2011; 22:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/25\">",
"      Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/26\">",
"      Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med 1977; 297:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/27\">",
"      Finsterer U, L&uuml;hr HG, Wirth AE. Effects of acute hypercapnia and hypocapnia on plasma and red cell potassium, blood lactate and base excess in man during anesthesia. Acta Anaesthesiol Scand 1978; 22:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/28\">",
"      SCRIBNER BH, FREMONT-SMITH K, BURNELL JM. The effect of acute respiratory acidosis on the internal equilibrium of potassium. J Clin Invest 1955; 34:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/29\">",
"      Magner PO, Robinson L, Halperin RM, et al. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis 1988; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/30\">",
"      COHEN JJ, BRACKETT NC Jr, SCHWARTZ WB. THE NATURE OF THE CARBON DIOXIDE TITRATION CURVE IN THE NORMAL DOG. J Clin Invest 1964; 43:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/31\">",
"      Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med 1993; 94:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/32\">",
"      Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/33\">",
"      Adrogu&eacute; HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/34\">",
"      Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/35\">",
"      DeFronzo RA, Sherwin RS, Dillingham M, et al. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings. J Clin Invest 1978; 61:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/36\">",
"      Sharma AM, Thiede HM, Keller F. Somatostatin-induced hyperkalemia in a patient on maintenance hemodialysis. Nephron 1991; 59:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/37\">",
"      Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/38\">",
"      Sargent AI, Overton CC, Kuwik RJ, et al. Octreotide-induced hyperkalemia. Pharmacotherapy 1994; 14:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/39\">",
"      Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/40\">",
"      Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106:c143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/41\">",
"      Sirken G, Raja R, Garces J, et al. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis 2004; 43:e31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/42\">",
"      Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/43\">",
"      Sever MS, Erek E, Vanholder R, et al. Serum potassium in the crush syndrome victims of the Marmara disaster. Clin Nephrol 2003; 59:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/44\">",
"      Perkins RM, Aboudara MC, Abbott KC, Holcomb JB. Resuscitative hyperkalemia in noncrush trauma: a prospective, observational study. Clin J Am Soc Nephrol 2007; 2:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/45\">",
"      Schaller MD, Fischer AP, Perret CH. Hyperkalemia. A prognostic factor during acute severe hypothermia. JAMA 1990; 264:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/46\">",
"      Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/47\">",
"      Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 1990; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/48\">",
"      Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 1986; 57:23F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/49\">",
"      Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/50\">",
"      Daut J, Maier-Rudolph W, von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/51\">",
"      Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/52\">",
"      Struthers AD, Quigley C, Brown MJ. Rapid changes in plasma potassium during a game of squash. Clin Sci (Lond) 1988; 74:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/53\">",
"      Thomson A, Kelly DT. Exercise stress-induced changes in systemic arterial potassium in angina pectoris. Am J Cardiol 1989; 63:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/54\">",
"      Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/55\">",
"      Knochel JP, Blachley JD, Johnson JH, Carter NW. Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs. J Clin Invest 1985; 75:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/56\">",
"      Sangkabutra T, Crankshaw DP, Schneider C, et al. Impaired K+ regulation contributes to exercise limitation in end-stage renal failure. Kidney Int 2003; 63:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/57\">",
"      Reza MJ, Kovick RB, Shine KI, Pearce ML. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/58\">",
"      Bandara V, Weinstein SA, White J, Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon 2010; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/59\">",
"      Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart 2003; 89:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/60\">",
"      Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/61\">",
"      Birch AA Jr, Mitchell GD, Playford GA, Lang CA. Changes in serum potassium response to succinylcholine following trauma. JAMA 1969; 210:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/62\">",
"      Cooperman LH. Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA 1970; 213:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/63\">",
"      Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/64\">",
"      Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 1999; 33:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/65\">",
"      Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant 2002; 17:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/66\">",
"      Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 2005; 365:1873.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.383, 898.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/68\">",
"      Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/69\">",
"      Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/70\">",
"      Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/71\">",
"      Luke RG, Allison ME, Davidson JF, Duguid WP. Hyperkalemia and renal tubular acidosis due to renal amyloidosis. Ann Intern Med 1969; 70:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/72\">",
"      Stokes JB. Potassium secretion by cortical collecting tubule: relation to sodium absorption, luminal sodium concentration, and transepithelial voltage. Am J Physiol 1981; 241:F395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/73\">",
"      Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998; 274:F817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/74\">",
"      Chakko SC, Frutchey J, Gheorghiade M. Life-threatening hyperkalemia in severe heart failure. Am Heart J 1989; 117:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/75\">",
"      Popovtzer MM, Katz FH, Pinggera WF, et al. Hyperkalemia in salt-wasting nephropathy. Study of the mechanism. Arch Intern Med 1973; 132:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/76\">",
"      Gonick HC, Kleeman CR, Rubini ME, Maxwell MH. Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971; 261:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/77\">",
"      Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 6:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/78\">",
"      Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int 1993; 43:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/79\">",
"      Bonilla S, Goecke IA, Bozzo S, et al. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest 1991; 88:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/80\">",
"      Bofill P, Goecke IA, Bonilla S, et al. Tissue-specific modulation of Na, K-ATPase alpha-subunit gene expression in uremic rats. Kidney Int 1994; 45:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/81\">",
"      Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007; 22:3471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/82\">",
"      Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/83\">",
"      Wrenger E, M&uuml;ller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/84\">",
"      Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/85\">",
"      Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant 2004; 19:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/86\">",
"      DeFronzo RA, Cooke CR, Goldberg M, et al. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med 1977; 86:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/87\">",
"      DeFronzo RA, Goldberg M, Cooke CR, et al. Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney Int 1977; 11:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/88\">",
"      DeFronzo RA, Taufield PA, Black H, et al. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med 1979; 90:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/89\">",
"      Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/90\">",
"      West ML, Marsden PA, Richardson RM, et al. New clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab 1986; 12:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/91\">",
"      Ethier JH, Kamel KS, Magner PO, et al. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990; 15:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/92\">",
"      Choi MJ, Ziyadeh FN. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol 2008; 19:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/5/33882/abstract/93\">",
"      Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens 2011; 20:547.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2377 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33882=[""].join("\n");
var outline_f33_5_33882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H783293332\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7397120\">",
"      BRIEF REVIEW OF POTASSIUM PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133155018\">",
"      Regulation of urinary potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Potassium adaptation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367758506\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCREASED POTASSIUM RELEASE FROM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pseudohyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H156422759\">",
"      - Technique of blood drawing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H156422766\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H446278642\">",
"      - Smaller effect in lactic acidosis or ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H129571552\">",
"      - Smaller effect in respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Insulin deficiency, hyperglycemia, and hyperosmolality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90534304\">",
"      - Causes other than diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased tissue catabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REDUCED URINARY POTASSIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reduced aldosterone secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774689278\">",
"      Reduced response to aldosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H774689287\">",
"      - Potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Voltage-dependent renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H270421097\">",
"      - Pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270420126\">",
"      Reduced distal sodium and water delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H270420133\">",
"      - Effective arterial blood volume depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270425989\">",
"      Acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270420140\">",
"      Multiple factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270419983\">",
"      Other mechanisms of impaired potassium secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Selective impairment in potassium secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H774690471\">",
"      - Pseudohypoaldosteronism type 2 (Gordon's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ureterojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H156422221\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156422773\">",
"      Exclude pseudohyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156422795\">",
"      Acute rise in serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873885\">",
"      Persistent hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H249933270\">",
"      - Urinary potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H249933336\">",
"      - Transtubular potassium gradient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H249933454\">",
"      - Diagnosis of hypoaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H783293332\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/18/17709\" title=\"figure 2\">",
"      Potassium adaptation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/26/18862\" title=\"figure 3\">",
"      Steady state response to K load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/25/9628\" title=\"figure 4\">",
"      Acidosis and K distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/46/9966\" title=\"figure 5\">",
"      Glucose and B blocker on K load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/22/13677\" title=\"figure 6\">",
"      Glucose induced hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/51/30525\" title=\"figure 7\">",
"      Beta blocker and potassium load",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2377|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9468\" title=\"table 1\">",
"      Major causes of hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/0/41995\" title=\"table 2\">",
"      Major causes of hypoaldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=related_link\">",
"      Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=related_link\">",
"      Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30425?source=related_link\">",
"      Overview of the management of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/34/15906?source=related_link\">",
"      Patient information: Hyperkalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10069?source=related_link\">",
"      Renal effects of ACE inhibitors in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_5_33883="Anaphylaxis severity with multiple stings";
var content_f33_5_33883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of systemic reaction in relation to number of Hymenoptera re-stings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Re-sting",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Grade of systemic reaction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       0",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       II",
"      </td>",
"      <td class=\"subtitle2\">",
"       III",
"      </td>",
"      <td class=\"subtitle2\">",
"       IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       First re-sting",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Later re-sting",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    X",
"    <sup>",
"     2",
"    </sup>",
"    = 8.31; p&lt;0.01.",
"    <br>",
"     Grade of systemic reaction in relation to number of re-stings according to HL Mueller",
"     <sup>",
"      [1]",
"     </sup>",
"     in 25 patients with relapses after discontinuation of VIT in relation to number of re-stings",
"     <sup>",
"      [2]",
"     </sup>",
"     .",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      1. Mueller, HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966;3:331.",
"      <br>",
"       2. Lerch, E, M&uuml;ller, UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606.",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33883=[""].join("\n");
var outline_f33_5_33883=null;
var title_f33_5_33884="Predictors of survival in HIV patients";
var content_f33_5_33884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of survival in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hazard ratio",
"       </td>",
"       <td class=\"subtitle1\">",
"        SE",
"       </td>",
"       <td class=\"subtitle1\">",
"        95% CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Younger group, no ART",
"        </p>",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Younger group, ART",
"        </p>",
"       </td>",
"       <td>",
"        0.415*",
"       </td>",
"       <td>",
"        0.109",
"       </td>",
"       <td>",
"        0.248-0.695",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Older group, no ART",
"        </p>",
"       </td>",
"       <td>",
"        2.364*",
"       </td>",
"       <td>",
"        0.613",
"       </td>",
"       <td>",
"        1.422-3.929",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Older group, ART",
"        </p>",
"       </td>",
"       <td>",
"        0.669",
"       </td>",
"       <td>",
"        0.200",
"       </td>",
"       <td>",
"        0.372-1.201",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Male sex",
"        </p>",
"       </td>",
"       <td>",
"        1.111",
"       </td>",
"       <td>",
"        0.287",
"       </td>",
"       <td>",
"        0.694-1.844",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         MSM",
"        </p>",
"       </td>",
"       <td>",
"        1.038",
"       </td>",
"       <td>",
"        0.228",
"       </td>",
"       <td>",
"        0.674-1.597",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4 cell count at time of enrollment (1 cell/mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        0.996*",
"       </td>",
"       <td>",
"        0.0006",
"       </td>",
"       <td>",
"        0.995-0.997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Year of enrollment in years (centered on 1996)",
"       </td>",
"       <td>",
"        1.155*",
"       </td>",
"       <td>",
"        0.058",
"       </td>",
"       <td>",
"        1.046-1.276",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Cox proportional hazard regression analysis of predictors of survival in patients, according to age group and ART status. After controlling for sex, homosexual behavior, CD4 cell count at enrollment, and the year of enrollment (centered on 1996), older untreated patients had 2.36 times the hazard of dying than did younger untreated patients. Younger patients treated with ART had a hazard of 0.415, which represents a 58.5 percent decrease in the hazard for death compared with younger untreated patients. Exposure to ART decreased the hazard of death in older patients to 0.669 relative to the younger untreated group, but this was not significant. Note that the estimated hazard ratio for the older treated group is &lt;1 as opposed to the older untreated group, when compared to younger untreated patients.",
"    </p>",
"    <div class=\"footnotes\">",
"     ART: antiretroviral therapy; MSM: men who have sex with men; Older group: patients aged 50 years; Younger group: patients aged &lt;50 years.",
"     <br>",
"      * P &lt;.01.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perez JL, Moore DR. Greater effect of highly active antiretroviral therapy on survival in people aged 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003; 36:212. Copyright &copy;2003 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33884=[""].join("\n");
var outline_f33_5_33884=null;
var title_f33_5_33885="Countercurrent mechanism CCT";
var content_f33_5_33885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Representation of the role of the cortical correcting tubule in the concentrating process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 178px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    NaCl reabsorption in the thick ascending limb, distal tubule, and connecting segment makes the tubular fluid entering the cortical collecting tubule dilute to the interstitium (100 versus 285 mosmol/kg). In the presence of ADH, water is reabsorbed down this osmotic gradient in the cortical collecting tubule, markedly reducing the volume of the fluid delivered to the medullary collecting tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33885=[""].join("\n");
var outline_f33_5_33885=null;
var title_f33_5_33886="Massive transfusion protocol";
var content_f33_5_33886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Massive transfusion protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"11%\">",
"     </colgroup>",
"     <colgroup width=\"89%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        University of Minnesota medical center, Fairview department of trauma services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Category:",
"        </strong>",
"       </td>",
"       <td>",
"        Provision of care, treatment and services department of trauma services",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Subject:",
"        </strong>",
"       </td>",
"       <td>",
"        Massive transfusion protocol",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Purpose:",
"        </strong>",
"       </td>",
"       <td>",
"        To ensure timely and appropriate treatment of or anticipation of massive transfusion episodes. To maximize the availability of blood and blood components, and to utilize resources efficiently.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Policy:",
"        </strong>",
"       </td>",
"       <td>",
"        The massive transfusion protocol (MTP) is a multidisciplinary process whereby blood and blood components are obtained rapidly for an exsanguinating patient. Initiation of the MTP is reported to the transfusion service physician (BB MD) on-call as soon as possible by the blood bank staff. The BB MD serves as a consultant in the evaluation and management of the patient's transfusion therapy during the massive transfusion episode.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"52\">",
"        <strong>",
"         Procedure:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Example reasons for initiation:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Replacement of at least one blood volume (8 to 10 red blood cell units in a 70 kg adult) within 24 hours or at least one half blood volume within 2 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Life-threatening trauma presenting to the emergency department",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Unexpected or anticipated surgical blood emergencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Trauma service responsibilities:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. The massive transfusion protocol (MTP) is initiated by the patient's staff physician or the staff anesthesiologist by calling the blood bank (this phone call may be delegated to another individual)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Clearly state to the blood bank: \"Initiate the massive transfusion protocol\". Indicate whether it is an adult MTP or pediatric MTP (for patient's less than 35 kg).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Give the patient's name and medical record number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Provide the patient's current location and a phone number that can be used to reach the patient's care team",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Determine if patient requires emergency release of two uncrossmatched and untagged O Neg red blood cells for immediate transfusion. Note: Average time for first MTP set is 15 to 20 minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Send a properly labeled specimen (3 mL purple tube) to the blood bank for a type and screen if not done in last three days. The specimen label must contain the patient's name, medical record number, date, and the initials of the collector written on the tube.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Record initiation of protocol in patient's chart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Blood bank responsibilities:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Release two emergency O Neg red blood cells (RBCs) if requested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Prepare 4 RBCs, 4 plasma, and 1 dose of platelets for adult MTP or 2 RBCs, 2 plasma, and &frac12; platelet apheresis for pediatric MTP. Note: Group \"O\" uncrossmatched RBCs will be issued, if necessary, until type specific and later crossmatched becomes available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Provide a cooler with ice for each set of RBC and plasma components",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Notify the patient's care team when a set of components is ready for pickup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Notify BB MD on-call",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Stay 1 MTP set ahead (prepare each set immediately following pickup of previous set)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Continue process until notified to discontinue the protocol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Nursing responsibilities:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Assign personnel to obtain the set of components from the blood bank",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Blood bank will call when each set is ready for pickup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Send a completed release form with the personnel picking up the components",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Order labs as directed by the trauma team",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Communicate the lab results to the trauma team and the blood bank",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Attending physician, surgeon, or anesthesiologist responsibilities:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Obtain baseline CBC and coagulation studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Determine if rFVIIa is required (see section below for guidelines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Monitor CBC, ABG, potassium, ionized calcium, and coag tests frequently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. If a coagulopathy is suspected measure the fibrinogen test and other coagulations studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Determine when the protocol should be discontinued",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Call the blood bank (this phone call may be delegated to another individual)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Document discontinuation in the patient's chart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Use of rFVIIa (Novaseven) in surgery and trauma:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Indication of the use of rFVIIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Active bleeding following administration of 6 to 8 units of red blood cells, 6 to 8 units of plasma, and one dose of platelets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Administer 10 units of cryoprecipitate if the fibrinogen is &lt;100 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Contraindications for the use of rFVIIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. pH &lt;7.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Immediately following cardiac arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Patient considered \"unsalvageable\" by staff surgeon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Recent thrombotic event, MI, or stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Dosing of rFVIIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. If the patient has been on warfarin and arrives with an elevated INR and rapid bleeding, consider using one small vial of rFVII or 1.2 mg. This is usually a 15 micrograms/kg dose for adults.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. If the patient is not on warfarin, consider using 45 micrograms/kg as a half dose and repeat this dose in 30 to 60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Always round down to the nearest full vial for doses of rFVIIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Review of massive transfusion protocol events by transfusion services:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Each event is summarized by blood bank staff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Review is performed by blood bank supervisor and transfusion service physicians",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. The events are reported to the transfusion committee",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         References:",
"        </strong>",
"       </td>",
"       <td>",
"        1. Technical Manual, American Association of Blood Banks. Bethesda, MD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Guidelines for Massive Transfusion, American Association of Blood Banks. Bethesda, MD.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Approved by:",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Dr. Matthew Byrnes",
"         <br/>",
"         Director of the Trauma Service",
"         <br/>",
"         Department of General Surgery",
"         <br/>",
"         University of Minnesota Medical Center, Fairview",
"        </p>",
"        <p>",
"         Dr. Donovan Hess",
"         <br/>",
"         Director of the Pediatric Trauma Service",
"         <br/>",
"         University of Minnesota Medical Center, Fairview",
"        </p>",
"        Transfusion Committee",
"        <br/>",
"        University of Minnesota Medical Center, Fairview",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Date effective:",
"        </strong>",
"       </td>",
"       <td>",
"        10/01/2007",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Date revised:",
"        </strong>",
"       </td>",
"       <td>",
"        May 16, 2008; April 6, 2010",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Date reviewed:",
"        </strong>",
"       </td>",
"       <td>",
"        April 6, 2010",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Original authors:",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         James Harmon, MD",
"         <br/>",
"         Department of General Surgery",
"         <br/>",
"         Trauma Service",
"         <br/>",
"         University of Minnesota Medical Center, Fairview",
"        </p>",
"        Julie Welbig",
"        <br/>",
"        Blood Bank Technical Supervisor",
"        <br/>",
"        University of Minnesota Medical Center, Fairview",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bracey A. Guidelines for Massive Transfusion, American Association of Blood Banks, Bethesda, MD 2005.",
"      </li>",
"      <li>",
"       Technical Manual, 16th ed, American Association of Blood Banks, Bethesda, MD 2008.",
"      </li>",
"     </ol>",
"     <br/>",
"     Data reproduced with permission from: the American Association of Blood Banks (AABB).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33886=[""].join("\n");
var outline_f33_5_33886=null;
var title_f33_5_33887="Knee chest examination position";
var content_f33_5_33887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee chest examination position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiimyOkUbPIyoijLMxwAPUmgB1FeTeMfj74H8NzS28N7Lq94nBi09fMUH0MhIX8ia8h139qHxBPOf7C0LTrOAHj7WzzOR77SoFK6RShKWyPreivkDT/2nPFsTj7bo2jXK9xGJIj+e5q7TRf2o9JlZU1rw5qNqf4ntpEnH5HaaLobpyXQ+i6K818OfG7wDrrbItdis5v8AnlfqYCfoW4P516La3MF3bpPazRzwOMrJGwZWHsRwaZBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyeWOCGSaZwkUal3ZjwoAySaAMTxv4r0vwZ4dudZ1uby7aHhVXl5XPREHdj/niviP4q/FfXfiDfOt1K9joyk+Vp0LkLj1kI++36DsKX44fEi5+Ifit5IXZNDsmaKxhzwwzgykf3mx+AwPWvOl4G4/hUNnRSp9WSbQF4G0dqRCofuajJJqQIQMdzUm5YSVV5AoRst161EyhcD0pnmY+7+dKxd7Giw2oGIBPaur8A+Otf8AA999o0K+CQk5ls5iWgm9mXsf9oYNcOZWONv601pCe/A6n1oV0EuWSs0ffPwp+KeifEOyK2jfZNXhQNcWErfOn+0p/jX3H44r0CvzV0DVL/R9Tt9S0i6ktNQtW3wzIcEH0PqD0I6Gvu74LePF+IXgiDVJY0h1CJzb3kSnhZVxkj2III+taJ3OKpT5NVsd5RRRVGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXAfHvVjovwi8TXSMVke1NuhH96QhP/AGau/rxn9rV2T4QTqp+V763Vvcbif5gUDW58TY2IqDsKc/GB6Ui/M9Ko3Sc1kdw5AEXeRz2qSHu7VG/zMAOlT3GFCqvpmkUivM+5vamKNxwKft/dlj+FSW42xs5GT2pk2uyOUheAeB1qwsKxQB5gTM33U7KPf3rY8I+E9a8SzXB0XS7nUBaIJJVgAJGeFH5g/lU0PhDxHeaibRNB1g3AJBiFlJuB9+MUBddTnVY5/pX07+xXNJ5Xi6DnyhLbye24q4P8hXkF78JPHGmeHJdauPD8sdoqNI4eVBLEg6syZyOPxr6z+A/gJfAXgeG2nZJNUviLq8kTpuI4Qeyjj65PeqijGtNONkej0UUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV/tO6c2ofBnWyilntTFcgD0WRcn8ia9UqlrWm2+saPe6berutruF4JB/ssCD/ADoBH5nxdc06P/WGtnxj4avPB/ie/wBB1JSJ7SXaHxgSIeUcexGDWKn+sNZM7ou6TFX1p0hzz7Ug4Rh3PSiT7gPtSK6DpCPKVR6VKwC26D8ahIyuKsNyEH4UFI+sP2QNNW38B6pqJGJbu/MecfwxoMfqzV6v4m8ZaJ4bkEGqXrC7MRnW1hRpZTGOr7VBIUYOWOAPWuF/ZdRU+EdoBjP2y53fXzD/AExXoeueGtG12W3l1bT4bqWDIjdshgp6qSCMqcDKnIOORQ9zjluzmvFd/F4g07wvBMt1aaPrGoLFcrPH5bugRnSNvRXdFHuDjvXow4rD8QaPba7ol1pd3uSGdNqvHw0TDlHX0ZWAI9wKq+BNbuNTsJ7HV9qa7pcn2a+RRgM2MrKo/uOuGH1I7VcGrGckdNRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHknx/+FUXj7RRf6WqR+JLFD9nY8C4TqYmP8j2PsTXyp4Z+FfjLX9bm0220S4tZ7dgtw94PKSDPQsT69sZzX6CSOsaM8jBUUZJPQCuK+HAe906/wDEM6kS65dtdx7hyLcYSAf98KG/4EaiRpCbWiPmfxb+zj4r0iwjutHubXXHC5mggHlSKf8AZDHDj8j7V5Dq+m6hpDtbazp95YTq2NtzC0Z/UV+kdQ3dtBewmG8ghuIiMFJkDr+RqLmiqSR+a8WHLAH3Bp8TZdVP4V9n2Hw98CeMo76DWPCljp+u2UphvYbRmhKE8pIpUjcjrhlJHqOoNY97+zN4PlcNZajrVpjt5ySD9VoLVbyLH7Jl6tx8Ob+3yN9tqcuR6B0Rh/WvbK4v4afD+y8A2l9Bp95NcrdsjN5kapt2KQOF6k55JrsZnMcMjrG0jKpYIuMsQOgz3NJmTd22ZHjPVZtC8K6nqdsITNaxeYqzAlWORxgcknOB74rI8Hafrt94kPiPxDYwaVMLAWItonDPOd+8ySYJAA6KuSRubJ5xXGWer67438TafomqyfZrNm+0appMOnyRyWYjYPEss0nDK5XHy4z2yM17dWkY2M5O4UUVk+IvEWmeHraOXVLjy2mbZDCimSWdv7qIuWY/QVZJrUV5xqGv+OdWlUeHtH07RrMj/Xa1IXnPpiGInb/wJs+wqP7N8RzCT/wlHh3zscD+yZNufr5uanmQ7M9LorxjUPEHxg0cMzaHoGtRj+KxZ1Yj/cZwc/TNYr/GXx3BGwm+H8nmrw2FuBg/Tyz/ADo5kUoNn0DRXzBN8cfH0NwZLnQNOtIu0Vxa3K8f7xArQ0v9o69LBb/w7aXBH3jZX2G/75df60uddTT6tUfwq/ofR9FeTaF8efCF+yR6ob7RZT1N7D+7z/10TI/E4r0/TdRstUtEutNu7e7tn+7LBIHU/iKpNPYylCUHaSsWqKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV5/rV7ceNNTudE0qaSDw/auYtUv4m2tcOOtrCw6f7bjp90c5wAeefHjXLTxLq2jaNaXf2jSxazXkjW8xCyPv8peVPO3bJ+NL4N+JOq+HYYbLXIH1bSIgEjuIFAurdBwAydJVA7jDexrT+OPhkWWm6X4i0e2VLbSIvsd3bwpgLZkjDKB/zzPOPQmvP7dlZVZSGUjII6EetdEKcZxsybtM+k/D+u6X4h08XuiX0F7bHgtE3Kn0YdVPsQDWlXzDb2z2+orqWl3U+m6oBj7VanDMPR1PyuPZga9E0H4pXliFh8X6eZIhx/aWmoXTHrJDyy+5XcPpXPUw8o6rU0jNPc7jxP4elv7u31bRblbDX7VCkVwy7o5oycmGZR96Mn8VPI75q2njKO2SSPxXZTaDdQpukkn+e1ftmOcfKc9lOG9q3NE1nTddsxdaNf219bn+OCQNj2I6g+xrAsoB4m8e3F1OPM0nw83kW0Z5WS9ZcySY7+WpVR6Fn71ilfQpu2ppWHi/w5qBxZa9pczf3RdIGH1BORW1DNFKA0UsTp6q4IqPUND0nUs/2jpljd56+fAj5/MViy/DrwhKct4e09fZItgP4DFVyE8xV+FaxT6RqeqKBJJqGp3Un2k8maNZWSM57qFUAdsDiu1qK1tobO2it7SGOG3iUJHHGoVUUdAAOgp080dvBJNPIscMal3djgKoGSSfStCTH8XeI7bw1pX2qeOS4uJXENraRcyXMzfdjUe/c9AASeBXM+HdKuIbmbWNceO48Q3QxLKmSltH2ghz0Qdz1Y5J7AZ2gvJ4n1lvFt8rLAyNDo9u4x5NuesxHZ5cZ9Qm0dzXVKazlLoWkTqakBrA1zUb6O7stK0OCKfV74O8ZnJ8q3iTAeaTHJALKAoxknqBk1nxeIJvD+o6pYeLb2CVLQW8i6hBbMiBJt4AlUFgmGjPzE4wRnFTyvcd0bnizWP+Ef8AC2rauITcGxtnnEQ/jKjgcdqXwzqdxqnh/TNQuoTa3F1bRzyQBifLLKCVz3xmtB2UxE8MrD6gj+oqGNhkgEccEA9P8KQy8spwdzHAGTk8CvLfFXiH4f64kyyaDb+I47eI3F5Pb2wU2sGQPN3naWyemwnIBI6V03xCmkfw3/Zls5W61iePTYip5AkP7wj6Rhzn2rjPEQF7a/EOTSvJECNYeHLLg+WpRlDDjsGmwcf3auMbkSlYqeLfgPF5Ulx4L1CSJxyLC+cvE3skn3l/HcPpXjdrJrngzXbiKxmvvD+sQEedCh2g+hZOUkU9jgg9jX1z4K1W71bR5ZNSWAXltdz2crW4IjkaJyu9QckA46ZNZHxW8AWvjjRP3eyDXLRS1jd46H/nm/qjdCO3UdKzce2520cU17tT3o+f6HLfDD42QatPb6P4xWGw1SQhIbyPi3uW7A5/1bn0PB7HtXtlfA91bv8Av7TULcxTIzQzwP1jdThlPuCOv419Lfs5+OJNc0KXw9q9wZdX0pR5cjn5ri2PCOfUr90/ge9XTqc2j3HjMIqaVSn8LPYqKKK1PPCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5nxVrd1a6toujaSY/t9/N5kjuu4Q2sZBlcj1OVQe757Vk/DIiHww2nkASabe3VnIB6rKxBP1VlP41H4Wk/tnX9e8Rt80cs39m2R9LeEkMR/vSlz9FWksnGjfEe9tHO211+3F5Ae32mEBJV+pj2N/wABNUlYR2LKkkbRyKrowKsrDIIPUEelfPHjTwq3gfWUjgU/8I5eyYsXPP2WQ8/Z2Pp1KH0+XsK+hwaqa1pdlrelXOnapbpc2dwmySN+hHsexHUEcg1cZOLugPnmE9KvQvjBzVLxfo+peBbxLa7juNS0+V8Wd5GBvde8bjvKo7D745HORUWlapaagm6yuI5ccMoOGU+hU8g/UV1RmpbENGidNspLsXYhMN4P+Xi2doZf++0IJ/Gum+FIvLLxzFp+n3t9Jpz2s93fRXE5mUu0i7XGfuuWLk+oBrlru+gsLZ57uQRxqO/Un0A7k9gK6b4XTy6R/Yvii5nZrHxMTZ3cRGBZTK7C3XnkdHjb/aYVnW5UttSke40UUVyFBXn/AMR7k6zqNn4RgY+RcL9r1Vl7WqnAiz2MjDb/ALqvXdXlzDZWk91cuI4IEaSRz0VVGSfyFeYeDhNd293r18rLe61L9rKt1ihxiGP8EwT7samTshpXOmTAACgKo4AAwAKkU1ApqVTWRoY9/enQfF1lrc9tcz6dJZSWNw9vC0rQNvEiOVUE7T8wJAODtzxWBN4itb3S/Ges28kLXWtCPS9MsXdfPkwpjTdHnK7nkdsEZCjJArq/Ednqd74evbXR4i13dL9lEm4KIVkO15Of7qljgd8VzPiDTo7bxFq9hoVtb2U+keHibQQwos08sisiuHxn5BHgYPV61i9NSGtSHxbqd94Wv4dO0W4kmFloiQPBJgxrcM6Q2zL33Ft+R0KqKseG9CsvD3jnULe1IU2mkW4vLiRvnuZnkd2mkJ68Iee2cVzbXiXWi6vrm5pIhfaRciaQH5oI0gY8nqAS5Pvmu/8AHfg+HxLIs0V01pdqvkSHbviuoN4YwzKCCyEjsQRk9iRSSuhN2Zn6Qt34pvp/EVqyw2dtby2+gtMpw8jjDXbDrtOAq/7OT/FWNaaLD4Y0fw54SkuvOjs2bX9bvmHDCJvMLHP9+XGM87UNenKVRFRFVVUBQqjAAHYDsK5j4kLFJ4PvjeTrDp6bJL35ctNArAtCvu5AT/gRqkrEN3ZnfA3VLy/8KXUWo2i29xBeSScMSXE2JwWz0bEoBHavSFNct4C0yfSvDcIv1A1K7d728x0E0h3FR7KML/wGumQ1jLc3Wx84/tI+GRpniaz8RWibbbVR9nuQBwLhBlW/4EgI+qe9eZ+HNeu/C3iLT9d0/LT2T5eMH/XQniSM/UdPcCvqv4xaF/wkXw31m0jXdcwxfa7f1EkXzjH1AI/Gvj5ZA6q6n5WAINZy0akj1sFJVaUqMj700bUrXWdJs9S06UTWd3Es0Ug/iVhkVcr58/ZZ8VsV1HwhdyZFuDe2GT/yyZv3iD/dY5+jV9B11Rd1c8epTdOTi+gUUUUyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArB8d6s+h+ENVv4Bm5jgZYAO8rfLGP8AvorW9XFfEY/a7/wvpHVbnUhcyj1jgUyH/wAeEdAFrw5piaJoOnaXEcraQJCW/vMB8zH3LZP41D4s0Z9a0yMWcy2+qWcy3dhcMMiKZemf9lgSrD0Y1qA5OakU1pYRzEHj3ToIxFr1tqGlaknE1q9nLKA3+w6KVdT2IPI9KveE/FI1+/1S1fTrvT3tDHJCl2mySeBwdsu08qCyuMHnjnGa3kdgMBiB9a5vxNZahb61p3iHRLU3t1bRva3dorqjXNs3zfKW43o4DAEjILDPNIDc1vS7LWdNnsNUto7qynG2SJ+h9CD1BHUEcg188eOvA48MXivq8C6jortst9VdcSw56RzsuCD2D9D3wevvOg+KtJ1u4ezgmkt9SQZk0+8jMFwn/AG6j3XI961bq3iuIJbe6iSa3lUpJHIoZXU9QQeCKqMraoD5ksNI02znE1vaIJh0kdmdl+hYnH4V6D8MI7bW9I8V+ENQYiCRheREH5kWbqy+6yoWHuRWF498Hy+CWa/07zJvCzH5gcs+mknoT1MPoTyvQ8c1W8DamNK8f6JdlwIbotp0xyMFZcFD/wB9qv8A31WsrThdCWjPcPAesXWo6ZNZ6uAut6ZJ9kvgOjuACsq/7LqVYfUjtXS1xFyx0f4l6ddA7bbXLVrGX0+0Q5kiJ9yhlH/ARXb1ylHCfFm4Nzp2m+HYyd+tXIimx2tkG+b8wAn/AAOnKRxgAAcADoKyb+5/tT4j6tcA7odJt49Oi9BI+JZT+XlD8K01NZyepcdidTVHxLrEeg+HNS1WXlbO3eUL/eYD5R+JwKuJkkAda898d3b+JNC1Y2QB0LS1ZpbrPF3dAFUij9VR2Us3TICjvUpXY27HpPwghuIfhj4bN9I8l3NZpcTM5JbfJ85z+LYrk/ifrlnofxI0a9vJoLdbbS5yZZCFzvlRQpPf7pOK7y71Gy8HeELeXUWKw2cEcCpGNzyvgKqIv8TMcACvJPHtneS6Te69rNit14y1WBtM0nT4VEhso3BLIn96QKXZ39sDA67WM72M+/KxeENb0211CS4sJrWU2No0a/uCcuFVxyy5PAPQV67oeopqeh6bfxOHS5topg3ruUGvnJpDd6FaWuk7996sdlagjDAvhBkeoGSfoa+irG2h07T7WxtuILaJII/91QAP5UkrBMul65O+/wCKk8YQ6b97SdFZLu9/uy3RGYYj6hB+8I9dlaPifWBomgX+pbBI9vEWjj/vyHhF/Fio/Gl8I6SdE0SG1mk869ctcXkx6zXDndIx/HgegAFKTshQV2dIjZ61OhqmjVYQ1kbCarfQ6bpN7fXau9vawPNKqDJKKpJAH0Br4RWWF5bgWhJtknkSLPXYGO3/AMdxX3RrVr/aGiajZj/l5tZYf++kI/rXwJpLFUmjIwQVOPT5QD+oNTLY7sA7VGdh4C1z/hG/HmgawWKxW90sc5H/ADxk+R8+wyD+FfdI56V+eUyiWGSM9HUr+dfcXwp1o+Ifhz4e1N23SzWaCUnu6ja36qaui9LCzGFpqfc6uiiitjzQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhNZJufihbKT8lhpDyAf7U0yr/KI13dcBbN5vxC8VS9fKisrcH0wjuR/4+KcdwN9TUimoFNSKa0ETqakU1ApqzbDc9IDJ8QaVouueRp+tw2807BpLdWbZMu3GXiYEMpGRyp4yKxyviPwuMq0/ifRV6o2BqFuPY8LOB6HD/71dD4m8PWfiC0ijuWmt7m3fzbW8t22TW0mMbkb6cEHII4INc/H4h1LwzMlr43ERtGYJDrtum2Bz2E6f8sW/wBrlD6jpUgbmkarpniHTDc6bPFeWcm6KRSvKno0ciHlT2KsK+fvij4Qn8GXBGlh/wCwbtt1hJnP2G5B3LCx/ukgbCf930r3HXPDAub4614eul0vXiozcKu6G7Xsk6Dh19G+8vY9qrWl5ZeMNO1Lw54k0/7LqCxbb7TZGz8h6TRP/GmRlXHIIwcGqUrAU/EF/wD8JH8MbTxHpyh7iCKDWYFHaSIh3X8g6/jXf2t7BdabDfRODbSxCdX7FCMg/lXnvwptRoOmXng++kea70uR2Bkxi4tZWZkkUenLKR2ZT7VQXUpNG+DXiTTS5N3o5uNIjJPJydsB9fuSR1DGV/A7NcaCNSkH73VZ5tQfPpI5K/8Ajm2ujU1h3GoaZ4b0gLfXkFvb2MCIQzDcFACrhRyc4wOOTXlHjPxvLq09jc/2VdjR4JG860lumVbqI/8APeNMFR3GC2P4lxWai5bFt2PUHuJ/GM8unaNPJBoaMY77VYjgzY+9Bbt3PZpBwvQZPTT8XWlvFo2haFYwpb2tzqdnaRwxjCrGr+YwA9NsZq34P13S9e8P211ogSK0QCL7OoC/ZyB/qyBwMcYxwRgjg0MPt/xF8OWo5WygudRkHoSBCmf++3x9KpKxne7M/wCJOt2OmfEPQDqBmvVitJ5LeytUM0sdzlQrmNecspZVY8A56ZzXF69r9/A2taqY45PEMFm6FVPmW+g25H3WYcPcucZUd8DhRk7PxKgs/DnjXdJrt7pema0kt7qSQIBJMY0SNY4pVUyAtwSoPAUkYzXI+ItXgPgS1urSzi0zw5M4GkaT92XUpyflln9IwRvK5JbGWPamJnK6fqa6XJpsNol6uo6SI5N9vHHKkUpQgq+9gGOGJwOea7bR/jBPFPHb+INMZg5CrLbxmKQ/9s2JVvor59q4OwtPsdqsW9pHJLySt1kcnLMfqalmiSeFoZkWSJ+GRhkGuj2CtvqDdz2LUtUs/E+qeGLPTLhLmyllbU52X+5BwqsDyD5rLkHuuDXcxtXhPwX1l7bXZdOmiha2vHnjguyP30jxBflZu/yhh6nZk5r3CNq456OxrFWRfjarCGqUbVZjaoKLsTYIPvXw3440R/D3j/xHZHHlpeP5Y6HaSXX8MOK+30avmz9p7Q/sniex1qMYj1C3ETn1li4/VWX/AL5pPY6MLLlqq541urrPh98S9Z8L6TcaK07voE0sqyLEMTW+4nLxMOR1zj8RXHbqrki2tZSuWI3Pz3PWoi7bHqVYKfxbH2r8KPH9vrqjw/qt3u8SWcW9t6lftcH8E69iSCNwHIOeMV6RXx/fWFzPFous6W0ker2MSlHifZIVKg4VjxuB5APB5B4NeqeBvjdbTRi08XRGCaPCvfQREIp/6bRffhPvynoa3hUUlqeXicJKlK8dj2yiq2n31pqVpHdafcwXVtIMpLC4dWHsRxVmtDiCiiigAopruqDLsqj1JxSRyxyDMbo4/wBk5oAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnehtv8AFXjR/wDqJRJ/3zbRf416JXnGgjHiTxmP+oqp/wDJaGqjuB0QNSKahU09TWgidTV204XNZ6mrsTYUCpAuA02aOOaF4pkSSJ1KujrlWB6gg9RUQenh6QHEy6ZqPggmfw/DPqPhsEmbSAd01oO7WpP3l9Yj/wABI6Vc1Sx0/wAa6RY6toOoJFfQEy6dqcIy0L9CjA8lT914z+hAI60NXJat4bvLHU59a8Hyw21/Md13YTZFrfH1bH+rk/6aAc/xA9kBzmqarNd2UXiYWf2XxH4YlMOr2KHJa3YDzQv95CuJUP8As465FQeIbK+v/G91pmkXVrb6X4gsYNRlvGQSOvksEJhUjaXZWiO48LgHBNGteJ7CHXLTWZ4JdL1a2UWms6VeAK81kxwZFP3ZVjY7gyk/KXBxnFU/DbnT/Gmi6Lcu23SBqOmW7n+NWEM0IJ/64nH/AACjcZtaj8MPC15pBsxZPDdZ8xdTVy14JP77Snlj6g/L7CvFdf0jUfDGt/2TrYRpXBe1u41xFdxjqQP4XH8Sduo4r6bL1zvjvw5beLPDlxp0+EnH720nH3oJ1+44/Hg+oJFaxbjsSzxH4Q3Umi/ESTT4Tiw1OP8A1Q6K4V2BH0KMPo/sK9YsvF+laP4u1O6fTrq4tkjjs73VbdWmW2dSzCJkAJ2gMSzLnBOG9a8k8BeGNa13UYtcjuZdGS3QQpKYdzSkh1laLJ42k4DEEZzxxXeeNdnh/wAHWei6GWs2upltomjY70QZeWTd1LFVbLdSWrCpJc2hSj1ZJ8WfiToeu+GbzS9DluLqF499xfxxERRKpB2fMB5hfG0qvYnJ7VveDPhvZX+iRal4+sbbVdfvo1eZZ4hstUx8sEaDhAoxnHfNcL4G0T/hKPHFnbTDfp2mbb+7B5DMD+5jP1YF8eie9fRJPrTQM8t1b4I+GZ976JNqGiTHp9lmLxA+8b5GPpivIfHfhvxB4FSaTVbX7dp4UmHUrOM+WW/hWVeTGScc8r719XFq4v4u6zFpXgTUI2CSXGor/Z9vE4yHeQEZx6Ku5j/u1opuOwrXPn60gm0TRNPltxuu9MaO746s6ndIPxBcfjX0DZ3MV1bw3Fu2+CZFkjYd1YZB/I14nGojREHzKihRu5yAMc13PwovS/h2TTJGzLpUzWwz1MR+aI/98nH/AAGueRoj0CNqtRt0qhG1WY2rMovRtXC/HTw9/wAJF8N9RESb7vT/APT4MdSUB3qPqhYV2sbVOAjqySKGjYFWU9weCPyoBNrVH5/hwwBU5B5BqK5+a3kXONwxmtLxLpjaF4k1fSW/5cruWAe6hjtP/fOKzCPMaOMdXkRfzYCotZntc/NC67HvNswSGJBwFRVGPpTb7TrLUSjXcAaVPuTISkifRxgiqyS4YgHgcVZjlrG56DimrMzbTR9Z0S6a68La7NZzMckN8m7/AHivyt/wJCfevVPBnxW1O009bbxxpd1NeKxAvdNiWSN17FkB3A9c4GK4aOSrCPWkaskcdXAUqnke7+JPFVtpENolpby6nqV9kWdlbEbpcDlix4RBkZY8DPc4FYZ0rxJrP7zxDrz2ETc/YNF/dhR6NOwLsf8AdCCvLFvtTt40Ok6nNYTxtvRlAZCf7rqfvIe449eoFek+BfGsfiNZLK/gWx122TfPahspImcebEx+8hP4qeD6mpVXLY8jE4OVB33XctL4B8L7t9xpKXknUyXkslwx+pdjSS+AfCbNuj0O1t5O0lsWhYfQoRiuiMlMMlZXZynPDSNe0T954Y1yW5iX/mHay5mjb2Wb/WIfruHtW/4V8VW2uyT2c0EunazagG50+4I8xAejqRw6Hs68fQ8UhkrC8T6S2qR291p8y2muWBMljeY+43eN/WN+jL+PUCtYVWtGFj0CisTwbr6eI9DjvDCba6R2gu7ZjlredDh0P0PQ9wQe9bddRIUUUUAFFFFABRRRQAUUUUAFec6V8njHxpGev223k/BraMf+ymvRq84X9z8TvFEZ4860spwPoJEJ/QVUdwN0GpFNQg1IprQRMp6VKslVwaQsVNAF1ZKkWSs9ZKkWSkBoCSnh6oLJUiyUrAReIdC0nxLpzWOvafb39qf4Jkzt91PVT7jFcfqHhnVtEa1m01T4j020kE0dnduFvLcqpUNFNwJMKSNsnOP4q7lZKkElFgOW0TxBp+t+cllK63UHE9pOhingPo8Z5H16HsTVbxfr39g6QZYY/tGo3Di3sbYdZp2Hyj6DliewBra8ReGtL8QeVLexSRX0H+ovrZzFcQ/7rjnH+ycg9xXnes6Trvh/xB/bPiAy69pkFv8AZ7e8tIQJLJScu8sC/eLcAyJ2X7oGaTk0ho1vDenHR9BsNPaXzXt4gryf336s34sTXA/EDVom8TXRmbFto9mEY+kkmHf8dioP+BV6FpupWGoRxS2V7bXEUieYrRyhspnr9K88+H/h6Xxd4yupr4Rzaba6hJfX8iMHimlD/uYFbowAVWbHTaB3rGKuy27Hq3wh8PS+H/CKS38ezVtTf7bdg9ULD5I/+AoFH1zXaF6jaTJ5PNRs9bJGZMWycDkmvn7x/rv/AAk/jOWSB92l6OXtLUjpJMeJpR9MBAfZvWu/+LfiefQ9AjsdLl8vWdVY29sw6wpj95N/wFen+0RXkdpbxWdrFb267YYlCKO+B6+/elJ9Coomq74Ovjpfjm1DHFvqsJtH9BMmXjP4jev5VSqpqcc0lk5tDi7hKz27ekiHcv6jH41myj3eNqtRtWD4f1WHWdEstVtyFguYVl5ONhPVT6EHI/CtS0uYZziCeKUjqI5Ax/Q1mM042qyjVRjarKNSGfJP7RVilj8VtTdODdxQ3JHuUCn9VrgdCj8/XdPTsJhIfooz/MCvWP2rIdnjrRpwP9dpu367ZD/jXnPgy2O+TUJBhSDHCPbPzN+OMVEtNT1cL78IxPQYpqtxS1iRy1bimrE9Y2opatRy1jRTe9W45qANZJKbcxSvJb3VjObXU7RvMtbkD/Vt3BHdGHDL3FVY5aspJRsTKKmnGWx614O8Sx+JNFW78v7PeRMYLu2zkwzAcr7qcgg9wRWyZa8U0TVT4f8AFFrqBbbYXpWyvh2GTiKU/wC6x2k+je1eqDUrR7k2yXls9wODEsylx/wHOaq3U+axFF0ajgzUMtMaWqRmqNpqDEr6Rc/2J8R4dp22XiGIxSDsLuFcq31aMMP+2Yr0yvGvG87QaCdRhz52lzxagmOv7pwWH4pvH417FDKk0KSxMGR1DKR3B6V00neJLH0UUVqIKKKKACiiigAooooAK871oCL4sHt9o0QY9ylwf6PXolef+L18v4l+HZegm069hz6kNC2P5047gaYNPBqIU8GtREqmm3XmfZpTbosk4UmNGbaGbHAJ7D3oBp4NAHKWvi+1iuI7PxBbT6DqDHasd7jypT/0zmHyN9Mg+1dMH4B7EZHvUlzBBeW0lveQxXFvIMPFKgdGHoQeDXMN4Pl0zL+D9Tk0tc5+wXANxZsfZCd0f/AGH0pAdMHqRZK49/E1zpB2eLtLl0xRx9vgJuLNvcuBuj/4Go+tdFa3UN1bpcWk0c9vIMpLE4dWHsRwaYGkslSLJVAPUgekBfWSpFlwcg81nrJ71IslFgON8XfC/QtavZNUsLW0s9XbJYvAJLe4PpLFxnPdlIb611PhvzYtAsorjTINKljTY1nbspjiIOPkI4KnGR3weeaurJTHfBpWAlaSq15eQ2lrNc3cyw20KNJLI5wEUDJJ/CkZ68m+LGvf2pfjwvaNm1h2zaowPDd47f8AHhm9sDvQ9AOWvtVm8S63c6/dI6C4Ais4n6w2wOVGOzN98/UDtRSGjtWRoLUQNzc6jbabpVs17q1znybdTjAHV3b+FB3Y/QZNMuJJzNbWlhbm71K8fyrW2U4Mj9yT2UDlj2Ar234deDYPCOnSNNIt3rV3hr29xgueyL/djXoB+PWk3YNzJ8J/CjS9P01Y/EUh1i4LtMYGZhZwuxy3lw5x17tk/TpW5dfD3wlcJhtBsI2H3Xgj8l19wyYIPvmumL+9MMlZXZVkcG0eoeEdTtre5urjUvD90/kxT3B33FnIfuq7fxxnoGPzA9cg11cbVauFSaMq6hh1wRVFTtOKAPnb9rchdb8Mv3+xXHP0da4DRsQ6XaRjgLEv8q7X9rW6V/EWh2w+/Dp0sh/4HJx/6DXDWLf6Hb46eWv8qzqHsZdsa0cvvVqOWspJKnjk96yPTNmKX3q3FN05rFilq1HL70AbcUtWo5fesWKWrcU3vQBoX1tDqen3FldAmCdDG2CQcHvXp/grw3oHi34W2iNpGm22pJC9q9xBAsckN1HlPMDqNwO4Bs5715VHL716X8Bb4re+JtKZvlEkN/EP99dj/rGD+Na030PMzOmnBT7Gqq3dnFFb6k6vexIqzOnRnAGWHsTzTGn966bxpp4e0+3xD54uJMd19fwrhmn96TVjxSfUgt3p13bSfcmheNvoVI/rXe/DO7N78PPDdw/3m0+DP1CAH+VeX6lfpZ6fd3MpxHDC8jfQKTXpvwvsZtN+HXhy0uQRNHYxbwexKgkfhnFbUeomdRRRRWxIUUUUAFFFFABRRRQAVwXxAynjPwW/96S8i/ODOP8Ax2u9rhfiWAmqeDZ+66t5WfZ4JRTW4FulBpKBWwiQGnqaiBp4NICVTUimoQaepoAnU9R2IwR61zF74I083D3egz3GgX7nc0lgQIpD/wBNIT8jfXAPvXSKakU0gOKlvfEeiA/23pQ1OzXrfaOpZgPV7djuH/ACwrT0bWtO1qBpdJvYbpV4cIfnjPo6n5lPsQK6ZTg8da5fx7o2iSaPqGt6hpxe9sbd51ubSQwXICjOBKvPbocj2ouBphqeHrD/ALC8V6fbxy6VqNpr1oyhli1EeRcAHoBMgKt/wJB9aqyeJJrDI17w/remlesi2xuov++4t36gUcyYHUrJQ7ZXPeuWj8b+GHOP7esEbussnlsPqGANZOsfFfwlp26ODUW1W86La6bE08jH04GB+JougNXx94nHhrRfMt1WbVbpvIsYG6PJj7x/2VHzH2GO9eQ2FsbWArJK09xIzSzzv96aRjlnP1P5DApbzU9T1zV5dZ1XSdZFwy+VBBHps7paw5zsB2cserN3PsBTftihC8tpqUCDq02nzoB+JSs5O5S0LVQ3dxFZ2stxcNtijXcxxk/QDuewFZreJdDVmVtWs1ZThleTaQfQg9KS0aXXdRS5066EVlp8iyQTqoZZrlSCCQeGRO47k+1Q9Ctz2X4V+E5NHt31zWoQuu3yACNufscHVYh/tHq57njoK70ye9cz4N8Sf8JFo/2iaNYL+BzBdwqchJQAcqe6sCGB9DW0ZazepRZaT3phk96qtLTGl96QFlpPeq7n5+KiMlYmvajemaLSNAVZdevARFkZW1To1xJ6KvYfxNgCmlcR8zftD6kNT+JGoOhLW1vbrZRv/CXQEuB9GY/kaydNOdOtT/0yX+VeqfGD4R6zpd5DL4Z06613TLi2SFoUAaSOdR8zsD1Dkli3Y59q4BvDniDS7WGLUvD2tW7IgUl7GQrwMdVBFZ1IvsevgqlOKXvdCmDUivVeWZIjiUSRn0eJ1P6io/tsBOAzsfRY2P8ASsuV9j0vaw/mX3mjuDoyNyrDBHtVeKe501Qsu+6s1GBIOZYx/tD+Ie45qxpllqWptt0zSdWvD/0xsZWH57cV0dj4C8bXePs/hXUl95zHD/6E1Uoy7GNSvRWrmkzNtblJokkidXjYZVlOQRV6OX3qt4i8Jaz4H1lLXWbVYIdQQzwNG4ZDIMeYoI78g4+pqCOX3qWrOxrSqKpHmRtRTe9d18Frkx/EkoDxdaXKpHukiMP/AEI15rFL7123wnv7Ox8d2F1fSCIGOS3WRjgLvA4P1KinB2ZljIOdGSR9BeInVNB1Bn+75LV46Z+K2/iz8QtJ0920OG7E11n9/FbqZZOOi4Xp75xXnvhxdQ8b+IV0SPTbaC0a3a6l+3zuC6q6jBWIg4JblSwyOta2u7Hz3K2uZLQ6DQtMl8eawmm2YL6Fbyq2p3g+4wUg/Z0P8TMQN2OFXPc4r6EAAAAGAK4HTvCWsW1lDZ/8JQ9jZxDalrpGnw20aD0XcHI/OrI8Gk8v4n8UsfX+0Nv6BQK1i4xVjOzZ2tFcV/wiV5D81j4u8Rwv286WO4X8nQ0Z8b6T8yS6X4itxyY2Q2VwR7EFo2P1C1XMhcrO1oqtplzJeWEFxNazWckiBmgmxvjPodpIz9DVmqEFFFFABRRRQAVxPxRXEHhqXtFrdsSfQEOv/s1dtXFfFjjQdNYcMur2RB9P3yj+RNNbgTUlK33jRWwgFPBplKDSAlU08GogaeDQBMDUimoFNSKaQE6msvxhH5/g/XosZ36fcLj6xtWiDUd+gl067jYZDwyKfxU0AXfCs32jwxo82c+ZZwv+aA1qVzXwzmM/w88NSMcsdOgBP0jA/pXS1kMxPGrSQ+EtaubXYt3DZTSwuyg7XVCVPPoRUXgXStN0vwzp40u0S3SaBJnYgGSRmUEs7dWYk8k0vxAfyvAfiN8kEabcYI9fKatDQIvJ0LToiMbLaNcemFAoAv1538bNZvNO8P2Njp80ltJql0LaS4iba8cYRnbaezELtz2zmvRK8z+Pip/wi+kyEfvU1a32HuMhgf8Ax0mk9hrc8kh0nTYYGhjsLXymGGDRhi3rknkn3NN0bTU0mBreC5uJLYf6qKZgwiHopxnH1zVnfRvrE2NbwRfvpfjeOFcm21iFopBnhZohuRvxXcv4Cu+13xLpmitHHf3QFzL/AKq1iUyzyf7sagsfrjFeceE/D+qeL9eiGjXDWFtpk+bjU9obY5UqYogeGk2tyTwvHU8V7n4Y8IaL4aV20y0H2qTma7mYyzzH1eRuT/KrUbkSlZnIWsnizVwG0zw4lhA3SfWLjy2x6+THub8CVrSj8J+I7hP9N8QWtux6izss4+hdjXe0VaiiLs4M/DlJ1/03xN4jnbvsuUhX8kQVat/hl4Rhy39jpJMwAknllkeWTHTc5bLfjXZUU7COR/4Vz4Y/hsJ1PYrezgj/AMfo/wCFeeHx9xNRjPqmp3Kn9JK66igDkv8AhANHXiOfWUB6hdVuefzekHgOxTiLV/EUSdlTVpgB/wCPV11FAHIHwOn8PiTxQp7Eakxx+YoXwS6HKeKvFAPveK380NdfRQB5l43+Fr+JNDltJPEmszzRHz7UXbxOizAHaSRGGxzggEcE18xK00Ms1veQtb3dvI0M8LdY5FOGX/PUYr7qr55/aS8HfY7qPxlp0eIZNtvqaqOnaOb8OFJ9CvpWVWHMro9DAYn2U+SWzPJI5ferG8SRsjZ2sMHBwcfWstHwanjkrkPoDTsI4LSPZbRJEp67RyT6k9SfrXoXwUuY4/iXCr533GnTxJ9QyMf0H6V5pHLV/S9ek8O6zpms26iS4s5wyQ55nDAq8S98spOODziqg/eObF0+ajKKPsOqGs6xp2iWZutXvreyt+geeQLk+g7k+wrm7a88V+KYI3060PhbTpFBM9+iy3rZHRYgSkf1Yk/7NbGieCtH0u7F9JFJqOq4wdQ1BzPP+BPCD2UAe1dKh3Pm3Ip2/iS91iMnw3ot3Mh+5d6gptYD7gEeYw+i4PrXO33hr4ialdyNqmt6W9kT8tpYyTWaY9GdQZD+DCvU6K0UUibtnHrceOkAH9meHWUcYF9MCfxMVP8At3jdTk6Fobj0XU5B/wC0a62imI5Mar4xTiTwxpsmehi1Y4H1zEKtaVqniG41GKDUvDcdnatnfcpqCSheCR8u0E5OB+NdFRQAUUUUAFcV8WuPDdi3ZdVsSf8Av+ldrXHfF4Y8AajN/FbvBcD6pMjf0oQDm+8frSU5/vt9aStxCUtFJQA8Gng1GKcDSAlBqRTUINPU0ATqaeBvBT+8MfnUKmpoT+8T6ikBmfCJs/DfQl/55wGL/vlmX+ldfXG/CPjwLaxngxXF1GR6YuJK7KshnK/FRzH8OPEhUkE2MqjHuuP6108CCOCNFGAqgAenFcn8W8/8K61pRnLxpHgd9zqMfrXX0AFeSftAXgEXhnT1b55b17kr/sxxMM/m6/nXrdfN3xO1Y6z8SNSdWzbaXGunQ+hf78p/Mqv/AAGlJ2RUVdmQXqpq11LbadPLbgG4wEiB/vsQq/qRTi9MwZrvTolPzvf2qrxnkzpjjvWS3NWz6a8G6Bb+GPDOn6RagbbeMB37ySHl3PqWYk/jW1RRWxgFFFFABRRRQAUUUUAFFFFABRRRQAVV1OwtdU065sNQhSe0uY2iliccMrDBBq1RQB8U+O/CN/4F164027huprBTus70RMySwnoGYDAdehB9M965+K7VziNJ5G9Egdj+QFfexAIwRkUgRV6KB9BWLopu56VPM6kYqLVz428NeDfFXiN0XSdDvEjc4+1XsZt4UHqS2GP0UE19FfDn4X6R4PVLyYDUteK4kv5l+56rEvSNfpye5NegUVcaajsc1fF1K+knp2CiiirOYKKKKACiiigAooooAKKKKACuP+L/APyTPxF/16nH1yK7CuN+LrZ8D3Nuel1c2tsfo88YP6E0ASP94/WkpX++31pK3EFJRS0AFKKbS0ASA09TUQNPBpASqaljOHX61ADUiHmgCh8LPl0LUYu0WrXqAeg89j/WuyrjfhoNsHiOP+5rd106clW/9mrsqxGcj8VjnwTcpn/W3NpHj1zcxgj8q66uP+KXPhu1T/npqdinv/x8x12FAAa+OdLuHmtWnmJM8080spPUu0jFifxr7Gr4+1CM2eu67aMNrQandJt9AZWYfowqZ7Fw3JTJWj4ShN/478L2gGd2oLMw/wBmJWk/morD8yu7+BOnnUPiLLfMpMWl2LEHsJJm2j/x1G/OojuVLY+jKKKK1MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4r4tc+HLFezatYg/wDf9K7WuK+LP/Ivaf8A9hax/wDR601uBM33j9aSlb7x+tFbCCiiigBKWkpaAAU8GmUoNICUGng1EDT1NAFX4eHGo+ME9NZZvzghNdlXFeADjX/GaHg/2lG+PY20PP6Gu1rJ7jOQ+JJ/0PQk/wCemtWQz6YkB/pXX1yHxEwz+FlxndrltgfQOf6V19IAr5c+MOnto/xN1QFdsOpRx38J/vHAST8Qyg/8CFfUdct4+8D6V42sbeHU/OhuLVi9tdW7BZIiRggZBBB7ggg4pNXGnZnylcXSwQPK+SqDoOST2A9yeBX038HfCcnhbworagoGragwurwAf6tioCxj2VcD65Pes7wp8G/D+hapBqN1cX2rXduwkh+2MvlxOOjBFUDI7E5x2r0ylFWHKVwoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4v4t8eFYG7LqVkT7f6RHXaVxnxeGPAt1L/wA8bi1lz6bbiM5PtQgJX+831pKWT77fWkrcQlLSUUAFLSUUALQKKKAHA08GohTwaQFTwMdvi7xjH2860kz9bdeP0rt64fwQceNfGC+osm/8gkf+y13FZPcZyPjzDap4PjPQ6wrY9dsMpFddXIeNPm8UeClHX+0ZWz7C2lrr6QBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVx3xgGfhrrrD+CESf98urf0rsaiu7aC8tpLe7hint5VKSRSqGVweoIPBFAHLPy5PvTa6oWtuAAIIsD/YFH2W3/54Rf8AfArTnFY5Wlrqfstv/wA8Iv8AvgUfZbf/AJ4Rf98CjnCxy1FdT9lt/wDnhF/3wKPstv8A88Iv++BRzhY5Wiuq+y2//PCL/vgUfZbf/nhF/wB8CjnCxy1KDXUfZbf/AJ4Rf98Cl+y2/wDzwi/74FHOFji/BHPjbxeewWxX8fKY/wBRXc1BBZ21vNNNb28MU023zXRArSbRgbiOuBwM1PUPUZyPiwbvGngpT0+1XLfiLZ/8a66oZbW3mngmmgikmgJMUjIC0ZIwSp7ZHHHapqQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_5_33887=[""].join("\n");
var outline_f33_5_33887=null;
